



US 20110039273A1

(19) **United States**

(12) **Patent Application Publication**
Tomigahara et al.

(10) **Pub. No.: US 2011/0039273 A1**
(43) **Pub. Date: Feb. 17, 2011**

(54) **METHOD FOR MEASURING DNA METHYLATION**

(86) PCT No.: **PCT/JP2009/057411**

(75) Inventors: **Yoshitaka Tomigahara, Osaka (JP); Hideo Satoh, Osaka (JP); Hirokazu Tarui, Osaka (JP)**

§ 371 (c)(1),
(2), (4) Date: **Nov. 2, 2010**

(30) **Foreign Application Priority Data**

Apr. 4, 2008 (JP) 2008-098006

Correspondence Address:

PANITCH SCHWARZE BELISARIO & NADEL LLP
ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200
PHILADELPHIA, PA 19103 (US)

Publication Classification

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
C07H 21/04 (2006.01)
G01N 33/543 (2006.01)
G01N 33/53 (2006.01)

(73) Assignee: **SUMITOMO CHEMICAL COMPANY, LIMITED, Chuo-ku, Tokyo (JP)**

(52) **U.S. Cl. 435/6; 536/23.1; 436/518; 436/94**


(57) **ABSTRACT**

(21) Appl. No.: **12/936,296**

The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.

(22) PCT Filed: **Apr. 6, 2009**

Fig.1



METHOD FOR MEASURING DNA METHYLATION

TECHNICAL FIELD

[0001] The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.

BACKGROUND ART

[0002] As a method for evaluating the methylation state of DNA in a target DNA region in a genomic DNA contained in a biological specimen, for example, there is known a method of measuring the content of methylated DNA in a target DNA region in a genomic DNA (see, for example, *Nucleic Acids Res.*, 1994, Aug. 11; 22(15): 2990-7, and *Proc. Natl. Acad. Sci. U.S.A.*, 1997, Mar. 18; 94(6): 2284-9 for reference). In such a measuring method, first, it is necessary to extract DNA containing the target DNA region from a DNA sample derived from a genomic DNA, and the extracting operation is complicated.

[0003] As a method of measuring the content of methylated DNA in a target region of extracted DNA, for example, (1) a method of amplifying a target region by subjecting the DNA to a chain reaction for DNA synthesis by DNA polymerase after modification of the DNA with a sulfite or the like (Polymerase Chain Reaction; hereinafter also referred to as PCR), and (2) a method of amplifying a target region by subjecting the DNA to PCR after digestion of the DNA using a methylation sensitive restriction enzyme are known. Both of these methods require time and labor for DNA modification for detection of methylation, subsequent purification of the product, preparation of a reaction system for PCR, and checking of DNA amplification.

DISCLOSURE OF THE INVENTION

[0004] It is an object of the present invention to provide a method of measuring the content of methylated DNA in a target DNA region (hereinafter, also referred to as a "target region") in a genomic DNA contained in a biological specimen in a simple and convenient manner.

[0005] That is, the present invention include the following inventions.

[Invention 1]

[0006] A method of quantifying or detecting methylated DNA in a target DNA region possessed by genomic DNA contained in a biological specimen, comprising:

[0007] First step of separating double-stranded DNA derived from genomic DNA comprising the target DNA region contained in the biological specimen into single-stranded DNA;

[0008] Second step of mixing the single-stranded DNA, a methylated DNA antibody, and a specific oligonucleotide comprising a nucleotide sequence of a part of a complementary sequence to any of the following nucleotide sequences and not inhibiting binding between the methylated target DNA region in the single-stranded DNA and the methylated DNA antibody, to form a complex of the single-stranded DNA, the methylated DNA antibody, and the specific oligonucleotide; and

[0009] Third step of detecting or quantifying the methylated DNA in the target DNA region contained in the biological

specimen by conducting detection or quantification depending on an identification function that is possessed by the methylated DNA antibody contained in the complex and available for detection:

[0010] (1) the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0011] (2) the nucleotide sequence of SEQ ID NO:2 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0012] (3) the nucleotide sequence of SEQ ID NO:3 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0013] (4) the nucleotide sequence of SEQ ID NO:4 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0014] (5) the nucleotide sequence of SEQ ID NO:5 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0015] (6) the nucleotide sequence of SEQ ID NO:6 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0016] (7) the nucleotide sequence of SEQ ID NO:7 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0017] (8) the nucleotide sequence of SEQ ID NO:8 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0018] (9) the nucleotide sequence of SEQ ID NO:9 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0019] (10) the nucleotide sequence of SEQ ID NO:10 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0020] (11) the nucleotide sequence of SEQ ID NO:11 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0021] (12) the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having 80% or more sequence identity to the sequence,

[0022] (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0023] (11) the complementary sequence to the nucleotide sequence of SEQ ID NO:2 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0024] (15) the complementary sequence to the nucleotide sequence of SEQ ID NO:3 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0025] (16) the complementary sequence to the nucleotide sequence of SEQ ID NO:4 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0026] (17) the complementary sequence to the nucleotide sequence of SEQ ID NO:5 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0027] (18) the complementary sequence to the nucleotide sequence of SEQ ID NO:6 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0028] (19) the complementary sequence to the nucleotide sequence of SEQ ID NO:7 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0029] (20) the complementary sequence to the nucleotide sequence of SEQ ID NO:8 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0030] (21) the complementary sequence to the nucleotide sequence of SEQ ID NO:9 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0031] (22) the complementary sequence to the nucleotide sequence of SEQ ID NO:10 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

[0032] (23) the complementary sequence to the nucleotide sequence of SEQ ID NO:11 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence, and

[0033] (24) the complementary sequence to the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence.

[Invention 2]

[0034] The method according to Invention 1, wherein the specific oligonucleotide comprises any of the following nucleotide sequences:

[0035] (1) the nucleotide sequence of SEQ ID NO:13,

[0036] (2) the nucleotide sequence of SEQ ID NO:14,

[0037] (3) the nucleotide sequence of SEQ ID NO:15,

[0038] (4) the nucleotide sequence of SEQ ID NO:16,

[0039] (5) the nucleotide sequence of SEQ ID NO:17,

[0040] (6) the nucleotide sequence of SEQ ID NO:18,

[0041] (7) the nucleotide sequence of SEQ ID NO:19,

[0042] (8) the nucleotide sequence of SEQ ID NO:20,

[0043] (9) the nucleotide sequence of SEQ ID NO:21,

[0044] (10) the nucleotide sequence of SEQ ID NO:22,

[0045] (11) the nucleotide sequence of SEQ ID NO:23

[0046] (12) the nucleotide sequence of SEQ ID NO:24,

[0047] (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:13,

[0048] (14) the complementary sequence to the nucleotide sequence of SEQ ID NO:14,

[0049] (15) the complementary sequence to the nucleotide sequence of SEQ ID NO:15,

[0050] (16) the complementary sequence to the nucleotide sequence of SEQ ID NO:16,

[0051] (17) the complementary sequence to the nucleotide sequence of SEQ ID NO:17,

[0052] (18) the complementary sequence to the nucleotide sequence of SEQ ID NO:18,

[0053] (19) the complementary sequence to the nucleotide sequence of SEQ ID NO:19,

[0054] (20) the complementary sequence to the nucleotide sequence of SEQ ID NO:20,

[0055] (21) the complementary sequence to the nucleotide sequence of SEQ ID NO:21,

[0056] (22) the complementary sequence to the nucleotide sequence of SEQ ID NO:22,

[0057] (23) the complementary sequence to the nucleotide sequence of SEQ ID NO:23, and

[0058] (24) the complementary sequence to the nucleotide sequence of SEQ ID NO:24.

[Invention 3]

[0059] The method according to Invention 1 or 2, wherein a counter oligonucleotide is added in forming the complex in Second step.

[Invention 4]

[0060] The method according to any one of Inventions 1 to 3, wherein formation of the complex in Second step is conducted in a reaction system containing a divalent cation.

[Invention 5]

[0061] The method according to any one of Inventions 1 to 4, wherein the methylated DNA antibody in the complex formed in Second step has been made to bind to a support before Third step.

[Invention 6]

[0062] The method according to any one of Inventions 1 to 5, further comprising, after First step and before Third step, the step of digesting unmethylated single-stranded DNA with a methylation sensitive restriction enzyme capable of digesting single-stranded DNA.

[Invention 7]

[0063] The method according to any one of Inventions 1 to 6, further comprising, after First step and before Third step, the step of digesting unmethylated single-stranded DNA with a methylation-sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide comprising a recognition sequence for the methylation sensitive restriction enzyme as a part thereof.

[Invention 8]

[0064] The method according to Invention 6, wherein the methylation sensitive restriction enzyme capable of digesting single-stranded DNA is HhaI.

[Invention 9]

[0065] The method according to any one of Inventions 1 to 8, wherein the methylated DNA antibody is a methylcytosine antibody.

[Invention 10]

[0066] The method according to any one of Inventions 1 to 9, wherein the biological specimen is mammalian blood, serum, plasma, bodily fluid, cell lysate or tissue lysate.

[Invention 11]

[0067] The method according to any one of Inventions 1 to 10, wherein the DNA sample derived from genomic DNA contained in the biological specimen is digested in advance with a restriction enzyme recognition cleaving site for which is not present in the target DNA region of the genomic DNA.

[Invention 12]

[0068] The method according to any one of Inventions 1 to 11, wherein the DNA sample derived from genomic DNA

contained in the biological specimen has been digested with a methylation sensitive restriction enzyme.

[Invention 13]

[0069] The method according to any one of Inventions 1 to 12, wherein the DNA sample derived from genomic DNA contained in the biological specimen has been digested with a methylation sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide.

[Invention 14]

[0070] The method according to any one of Inventions 7, 12 and 13, wherein the methylation sensitive restriction enzyme is HpaII or HhaI.

[Invention 15]

[0071] The method according to any one of Inventions 1 to 14, wherein the DNA sample derived from genomic DNA contained in the biological specimen is a DNA sample purified in advance.

[Invention 16]

[0072] The method according to any one of Inventions 1 to 15, wherein the target DNA region possessed by genomic DNA comprises a recognition cleaving site for the methylation sensitive restriction enzyme.

[Invention 17]

[0073] DNA comprising any of the following sequences:

[0074] (1) the nucleotide sequence of SEQ ID NO:13,

[0075] (2) the nucleotide sequence of SEQ ID NO:14,

[0076] (3) the nucleotide sequence of SEQ ID NO:15,

[0077] (4) the nucleotide sequence of SEQ ID NO:16,

[0078] (5) the nucleotide sequence of SEQ ID NO:17,

[0079] (6) the nucleotide sequence of SEQ ID NO:18,

[0080] (7) the nucleotide sequence of SEQ ID NO:19,

[0081] (8) the nucleotide sequence of SEQ ID NO:20,

[0082] (9) the nucleotide sequence of SEQ ID NO:21,

[0083] (10) the nucleotide sequence of SEQ ID NO:22,

[0084] (11) the nucleotide sequence of SEQ ID NO:23

[0085] (12) the nucleotide sequence of SEQ ID NO:24,

[0086] (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:13,

[0087] (14) the complementary sequence to the nucleotide sequence of SEQ ID NO:14,

[0088] (15) the complementary sequence to the nucleotide sequence of SEQ ID NO:15,

[0089] (16) the complementary sequence to the nucleotide sequence of SEQ ID NO:16,

[0090] (17) the complementary sequence to the nucleotide sequence of SEQ ID NO:17,

[0091] (18) the complementary sequence to the nucleotide sequence of SEQ ID NO:18,

[0092] (19) the complementary sequence to the nucleotide sequence of SEQ ID NO:19,

[0093] (20) the complementary sequence to the nucleotide sequence of SEQ ID NO:20,

[0094] (21) the complementary sequence to the nucleotide sequence of SEQ ID NO:21,

[0095] (22) the complementary sequence to the nucleotide sequence of SEQ ID NO:22,

[0096] (23) the complementary sequence to the nucleotide sequence of SEQ ID NO:23, and

[0097] (24) the complementary sequence to the nucleotide sequence of SEQ ID NO:24.

BRIEF DESCRIPTION OF THE DRAWINGS

[0098] FIG. 1 is a drawing showing a result of Example 1. The open box represents a measurement result of an index value having correlation with methylation frequency using genomic DNA of a noncancerous tissue, and the closed box represents a measurement result of an index value having correlation with methylation frequency using genomic DNA extracted from Capan-2 (a cancer cell strain). In the drawing, from the left side, A represents an amount of the methylcytosine antibody binding to the target region detected by using a specific oligonucleotide solution A, B represents an amount of the methylcytosine antibody binding to the target region detected by using a specific oligonucleotide solution B, and C represents an amount of the methylcytosine antibody binding to the target region detected by using a specific oligonucleotide solution C, respectively measured by fluorescence (612 nm).

MODE FOR CARRYING OUT THE INVENTION

[0099] As the "biological specimen", for example, a cell lysate, a tissue lysate (here the term "tissue" is used in a broad sense including blood and lymph node) or biological samples including bodily fluids such as blood, plasma, serum and lymph, and bodily secretions (urine, milk and so on) and genomic DNA obtained by extracting these biological samples in mammals. Other examples of the biological specimen include samples derived from microorganisms and viruses, and genomic DNA of microorganisms or viruses. When the specimen is human blood, use of the present invention in a health check or a simple clinical examination is expected.

[0100] As the DNA sample derived from genomic DNA contained in such a biological specimen, a sample treated with a methylation sensitive restriction enzyme or the like, a sample digested in advance with a restriction enzyme whose recognition cleaving site does not exist in the target DNA region possessed by the genomic DNA, a sample digested with a methylation sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide, a DNA sample purified in advance, and the like are recited.

[0101] For obtaining a genomic DNA from a specimen derived from a mammal, for example, DNA may be extracted using a commercially available DNA extraction kit.

[0102] When blood is used as a specimen, plasma or serum is prepared from blood in accordance with a commonly used method, and using the prepared plasma or serum as a specimen, free DNA (including DNA derived from cancer cells such as gastric cancer cells) contained in the specimen is analyzed. This enables analysis of DNA derived from cancer cells such as gastric cancer cells while avoiding DNA derived from hemocytes, and improves the sensitivity of detection of cancer cells such as gastric cancer cells and a tissue containing the same.

[0103] Usually, a gene (a genomic DNA) consists of four kinds of bases. In these bases, such a phenomenon is known that only cytosine is methylated, and such methylation modification of DNA is limited to cytosine in a nucleotide sequence represented by 5'-CG-3' (C represents cytosine, and

G represents guanine. Hereinafter, the nucleotide sequence is also referred to as "CpG"). The site to be methylated in cytosine is its position 5. In DNA replication prior to cell division, only cytosine in "CpG" of a template chain is methylated immediately after replication, however, cytosine in "CpG" of a newly-generated strand is immediately methylated by the action of methyltransferase. Accordingly, the methylation state of DNA will be passed to new two sets of DNA even after DNA replication. The term "methylated DNA" in the present invention means DNA occurring by such methylation modification.

[0104] It is known that methylation abnormality of DNA occurs in various diseases (for example, cancer), and it is supposed that the level of a particular disease can be measured by detecting the DNA methylation abnormality. For example, when the present invention is practiced for the region where methylation occurs at 100% in a specimen derived from a disease, the amount of methylated DNA quantified or detected will be large, whereas when the present invention is practiced for the region where methylation does not occur at 100% in a specimen derived from a disease, the amount of methylated DNA quantified or detected will be close to approximately zero. For example, when there is a region where a methylation rate is low in a specimen of a healthy subject and high in a specimen of a diseased patient, and if the present invention is practiced for the region, the amount of methylated DNA quantified or detected will be a value near zero in a healthy subject, but will be significantly higher than that value in a diseased patient, so that the level of the disease can be determined based on a difference between these values. The term "level of disease" is similar to the meaning that is generally used in the art, and concretely means, for example, malignancy of a cell when the specimen is a cell, or means, for example, abundance or the like of disease cells in a tissue when the specimen is a tissue. Further, when the specimen is plasma or serum, it means the probability that the individual has the disease. Therefore, by examining the methylation abnormality of the specimen by practice of the present invention, it is possible to diagnose a variety of diseases.

[0105] The term "target DNA region" means a DNA region for which presence or absence of methylation of cytosine contained in the region is to be examined, and a DNA region containing at least one cytosine in a nucleotide sequence represented by CpG which is present in a nucleotide sequence of a promoter region, an untranslated region, or a translated region (coding region) of a useful protein gene such as Lysyl oxidase, HRAS-like suppressor, bA305P22.2.1, Gamma filamin, HAND1, Homologue of RIKEN 2210016F16, FLJ32130, PPARG angiopoietin-related protein, Thrombomodulin, p53-responsive gene 2, Fibrillin2, Neurofilament3, disintegrin and metalloproteinase domain 23, G protein-coupled receptor 7, G-protein coupled somatostatin and angiotensin-like peptide receptor, and Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 can be recited. In addition to quantifying or detecting methylated DNA in the target DNA region individually, by using more target DNA regions in one detection system, for example, the quantification accuracy and detection sensitivity will improve accordingly.

[0106] To be more specific, when the useful protein gene is a Lysyl oxidase gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated

region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Lysyl oxidase gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:119 (corresponding to a nucleotide sequence represented by base No. 16001 to 18661 in the nucleotide sequence described in Genbank Accession No. AF270645) can be recited. In the nucleotide sequence of SEQ ID NO:119, ATG codon encoding methionine at amino terminal of Lysyl oxidase protein derived from human is represented in base No. 2031 to 2033, and a nucleotide sequence of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:119, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:119 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1560, 1574, 1600, 1623, 1635, 1644, 1654, 1661, 1682, 1686, 1696, 1717, 1767, 1774, 1783, 1785, 1787, 1795 and so on in the nucleotide sequence of SEQ ID NO:119 can be recited.

[0107] Also to be more specific, when the useful protein gene is a HRAS-like suppressor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HRAS-like suppressor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:120 (corresponding to a nucleotide sequence represented by base No. 172001 to 173953 in the nucleotide sequence described in Genbank Accession No. AC068162) can be recited. In the nucleotide sequence of SEQ ID NO:120, the nucleotide sequence of exon 1 of a HRAS-like suppressor gene derived from human is represented in base No. 1743 to 1953. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:120, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:120 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1316, 1341, 1357, 1359, 1362, 1374, 1390, 1399, 1405, 1409, 1414, 1416, 1422, 1428, 1434, 1449, 1451, 1454, 1463, 1469, 1477, 1479, 1483, 1488, 1492, 1494, 1496, 1498, 1504, 1510, 1513, 1518, 1520 and so on in the nucleotide sequence of SEQ ID NO:120 can be recited.

[0108] Also to be more specific, when the useful protein gene is a bA305P22.2.1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a bA305P22.2.1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:121 (corresponding to a nucleotide sequence represented by base

No. 13001 to 13889 in the nucleotide sequence described in Genbank Accession No. AL121673) can be recited. In the nucleotide sequence of SEQ ID NO:121, ATG codon encoding methionine at amino terminal of bA305P22.2.1 protein derived from human is represented in base No. 849 to 851, and a nucleotide sequence of the above exon 1 is represented in base No. 663 to 889. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:121, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:121 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 335, 337, 351, 363, 373, 405, 424, 427, 446, 465, 472, 486 and so on in the nucleotide sequence of SEQ ID NO:121 can be recited.

[0109] Also to be more specific, when the useful protein gene is a Gamma filamin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Gamma filamin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:122 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 63528 to 64390 in the nucleotide sequence described in Genbank Accession No. AC074373) can be recited. In the nucleotide sequence of SEQ ID NO:122, ATG codon encoding methionine at amino terminal of Gamma filamin protein derived from human is represented in base No. 572 to 574, and a nucleotide sequence of the above exon 1 is represented in base No. 463 to 863. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:122, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:122 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 333, 337, 350, 353, 360, 363, 370, 379, 382, 384, 409, 414, 419, 426, 432, 434, 445, 449, 459, 472, 474, 486, 490, 503, 505 and so on in the nucleotide sequence of SEQ ID NO:122 can be recited.

[0110] Also to be more specific, when the useful protein gene is a HAND1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HAND1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:123 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 24303 to 26500 in the nucleotide sequence described in Genbank Accession No. ACO26688) can be recited. In the nucleotide sequence of SEQ ID NO:123, ATG codon encoding methionine at amino terminal of HAND1 protein derived from human is represented in base No. 1656 to 1658, and a nucleotide sequence of the above exon 1 is

represented in base No. 1400 to 2198. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:123, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:123 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1153, 1160, 1178, 1187, 1193, 1218, 1232, 1266, 1272, 1292, 1305, 1307, 1316, 1356, 1377, 1399, 1401, 1422, 1434 and so on in the nucleotide sequence of SEQ ID NO:123 can be recited.

[0111] Also to be more specific, when the useful protein gene is a Homologue of RIKEN 2210016F16 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Homologue of RIKEN 2210016F16 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:124 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 157056 to 159000 in the nucleotide sequence described in Genbank Accession No. AL354733) can be recited. In the nucleotide sequence of SEQ ID NO:124, a nucleotide sequence of exon 1 of a Homologue of a RIKEN 2210016F16 gene derived from human is represented in base No. 1392 to 1945. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:124, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:124 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1172, 1175, 1180, 1183, 1189, 1204, 1209, 1267, 1271, 1278, 1281, 1313, 1319, 1332, 1334, 1338, 1346, 1352, 1358, 1366, 1378, 1392, 1402, 1433, 1436, 1438 and so on in the nucleotide sequence of SEQ ID NO:124 can be recited.

[0112] Also to be more specific, when the useful protein gene is a FLJ32130 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a FLJ32130 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:125 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 1 to 2379 in the nucleotide sequence described in Genbank Accession No. AC002310) can be recited. In the nucleotide sequence of SEQ ID NO:125, ATG codon encoding methionine at amino terminal of FLJ32130 protein derived from human is represented in base No. 2136 to 2138, and a nucleotide sequence assumed to be the above exon 1 is represented in base No. 2136 to 2379. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:125, in particular, cytosine in CpG which is

present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:125 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1714, 1716, 1749, 1753, 1762, 1795, 1814, 1894, 1911, 1915, 1925, 1940, 1955, 1968 and so on in the nucleotide sequence of SEQ ID NO:125 can be recited.

[0113] Also to be more specific, when the useful protein gene is a PPARG angiopoietin-related protein gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a PPARG angiopoietin-related protein gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:126 can be recited. In the nucleotide sequence of SEQ ID NO:126, ATG codon encoding methionine at amino terminal of PPARG angiopoietin-related protein derived from human is represented in base No. 717 to 719, and a nucleotide sequence of the 5' side part of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:126, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:126 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 35, 43, 51, 54, 75, 85, 107, 127, 129, 143, 184, 194, 223, 227, 236, 251, 258 and so on in the nucleotide sequence of SEQ ID NO:126 can be recited.

[0114] Also to be more specific, when the useful protein gene is a Thrombomodulin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Thrombomodulin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:127 (corresponding to a nucleotide sequence represented by base No. 1 to 6096 in the nucleotide sequence described in Genbank Accession No. AF495471) can be recited. In the nucleotide sequence of SEQ ID NO:127, ATG codon encoding methionine at amino terminal of Thrombomodulin protein derived from human is represented in base No. 2590 to 2592, and a nucleotide sequence of the above exon 1 is represented in base No. 2048 to 6096. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:127, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO:127 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1551, 1571, 1579, 1581, 1585, 1595, 1598, 1601, 1621, 1632, 1638, 1645, 1648,

1665, 1667, 1680, 1698, 1710, 1724, 1726, 1756 and so on in the nucleotide sequence of SEQ ID NO:127 can be recited.

[0115] Also to be more specific, when the useful protein gene is a p53-responsive gene 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a p53-responsive gene 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:128 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 113501 to 116000 in the nucleotide sequence described in Genbank Accession No. AC009471) can be recited. In the nucleotide sequence of SEQ ID NO:128, a nucleotide sequence of exon 1 of a p53-responsive gene 2 gene derived from human is represented in base No. 1558 to 1808. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:128 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1282, 1284, 1301, 1308, 1315, 1319, 1349, 1351, 1357, 1361, 1365, 1378, 1383 and so on in the nucleotide sequence of SEQ ID NO:128 can be recited.

[0116] Also to be more specific, when the useful protein gene is a Fibrillin2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Fibrillin2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:129 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 118801 to 121000 in the nucleotide sequence described in Genbank Accession No. AC113387) can be recited. In the nucleotide sequence of SEQ ID NO:129, a nucleotide sequence of exon 1 of a Fibrillin2 gene derived from human is represented in base No. 1091 to 1345. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:129 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 679, 687, 690, 699, 746, 773, 777, 783, 795, 799, 812, 823, 830, 834, 843 and so on in the nucleotide sequence of SEQ ID NO:129 can be recited.

[0117] Also to be more specific, when the useful protein gene is a Neurofilament3 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Neurofilament3 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:130 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 28001 to 30000 in the

nucleotide sequence described in Genbank Accession No. AF106564) can be recited. In the nucleotide sequence of SEQ ID NO:130, a nucleotide sequence of exon 1 of a Neurofilament3 gene derived from human is represented in base No. 614 to 1694. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:130 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 428, 432, 443, 451, 471, 475, 482, 491, 499, 503, 506, 514, 519, 532, 541, 544, 546, 563, 566, 572, 580 and so on in the nucleotide sequence of SEQ ID NO:130 can be recited.

[0118] Also to be more specific, when the useful protein gene is a disintegrin and metalloproteinase domain 23 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:131 (corresponding to a nucleotide sequence represented by base No. 21001 to 23300 in the nucleotide sequence described in Genbank Accession No. AC009225) can be recited. In the nucleotide sequence of SEQ ID NO:131, a nucleotide sequence of exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human is represented in base No. 1194 to 1630. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:131 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 998, 1003, 1007, 1011, 1016, 1018, 1020, 1026, 1028, 1031, 1035, 1041, 1043, 1045, 1051, 1053, 1056, 1060, 1066, 1068, 1070, 1073, 1093, 1096, 1106, 1112, 1120, 1124, 1126 and so on in the nucleotide sequence of SEQ ID NO:131 can be recited.

[0119] Also to be more specific, when the useful protein gene is a G protein-coupled receptor 7 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G protein-coupled receptor 7 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:132 (corresponding to a nucleotide sequence represented by base No. 75001 to 78000 in the nucleotide sequence described in Genbank Accession No. AC009800) can be recited. In the nucleotide sequence of SEQ ID NO:132, a nucleotide sequence of exon 1 of a G protein-coupled receptor 7 gene derived from human is represented in base No. 1666 to 2652. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:132 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented

by base Nos. 1480, 1482, 1485, 1496, 1513, 1526, 1542, 1560, 1564, 1568, 1570, 1580, 1590, 1603, 1613, 1620 and so on in the nucleotide sequence of SEQ ID NO:132 can be recited.

[0120] Also to be more specific, when the useful protein gene is a G-protein coupled somatostatin and angiotensin-like peptide receptor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:133 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 57001 to 60000 in the nucleotide sequence described in Genbank Accession No. AC008971) can be recited. In the nucleotide sequence of SEQ ID NO:133, a nucleotide sequence of exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human is represented in base No. 776 to 2632. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:133 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 470, 472, 490, 497, 504, 506, 509, 514, 522, 540, 543, 552, 566, 582, 597, 610, 612 and so on in the nucleotide sequence of SEQ ID NO:133 can be recited.

[0121] Also to be more specific, when the useful protein gene is a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO:134 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 78801 to 81000 in the nucleotide sequence described in Genbank Accession No. AC026802) can be recited. In the nucleotide sequence of SEQ ID NO:134, a nucleotide sequence of exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human is represented in base No. 1479 to 1804. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO:134 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1002, 1010, 1019, 1021, 1051, 1056, 1061, 1063, 1080, 1099, 1110, 1139, 1141, 1164, 1169, 1184 and so on in the nucleotide sequence of SEQ ID NO:134 can be recited.

[0122] As concrete examples of the "target DNA region" in genomic DNA, the following nucleotide sequences of SEQ ID NOs: 1 to 12, and complementary sequences thereof can be

recited, and also nucleotide sequences having sequence identity of 80% or more, 90% or more, 95% or more or 98% or more to these nucleotide sequences can be recited.

[0123] SEQ ID NO:1 corresponds to the nucleotide sequence represented by base No.21965410 to 21964273 in the nucleotide sequence described in Genbank Accession No.NT_008413.17.

[0124] SEQ ID NO:2 corresponds to the nucleotide sequence represented by base No.29857545 to 29858420 in the nucleotide sequence described in Genbank Accession No.NT_024524.13.

[0125] SEQ ID NO:3 corresponds to the nucleotide sequence represented by base No.7188979 to 7189574 in the nucleotide sequence described in Genbank Accession No.NT_010718.15.

[0126] SEQ ID NO:4 corresponds to the nucleotide sequence represented by base No.7534656 to 7535486 in the nucleotide sequence described in Genbank Accession No.NW_926584.1.

[0127] SEQ ID NO:5 corresponds to the nucleotide sequence represented by base No.21984168 to 21984790 in the nucleotide sequence described in Genbank Accession No.NT_008413.17.

[0128] SEQ ID NO:6 corresponds to the nucleotide sequence represented by base No.21818162 to 21818836 in the nucleotide sequence described in Genbank Accession No.NW_924062.1.

[0129] SEQ ID NO:7 corresponds to the nucleotide sequence represented by base No.21998877 to 21999061 in the nucleotide sequence described in Genbank Accession No.NT_008413.17.

[0130] SEQ ID NO:8 corresponds to the nucleotide sequence represented by base No.19277002 to 19277451 in the nucleotide sequence described in Genbank Accession No.NT_023935.17.

[0131] SEQ ID NO:9 corresponds to the nucleotide sequence represented by base No.19064265 to 19065579 in the nucleotide sequence described in Genbank Accession No.NW_924484.1.

[0132] SEQ ID NO:10 corresponds to the nucleotide sequence represented by base No.50318280 to 50318573 in the nucleotide sequence described in Genbank Accession No.NT_022517.17.

[0133] SEQ ID NO:11 corresponds to the nucleotide sequence represented by base No.61176814 to 61177405 in the nucleotide sequence described in Genbank Accession No.NT_022517.17.

[0134] SEQ ID NO:12 corresponds to the nucleotide sequence represented by base No.14488398 to 14489126 in the nucleotide sequence described in Genbank Accession No.NT_034772.5.

[0135] As the “target DNA region” (hereinafter, also referred to as a “target region”), a DNA region containing at least one cytosine in a nucleotide sequence represented by CpG which is present in a nucleotide sequence of a promoter region, an untranslated region, or a translated region (coding region) of a gene such as MLH1, RUNX3, CDH1, TIMP3, CSPG, RAR β , 14-3-3 σ , CALCA, HIC1, ESR1, PTEN, SOCS1, BLT1, ESR2, MTMG, TWIST, INK4, CDKN2, GSTP, DCR2, TP73, PGR, HIC2, MTHFR, TFF1, MLLT7, SLC5A8, THBS1, SOCS2, ACTB, CDH13, FGF18, GSTM3, HSD17B4, HSPA2, PPP1R13B, PTGS2, SYK, TERT, TITF1, BRCA1, AATF, ABCB1, ABCC1, ABI1, ABL1, AF1Q, AF3P21, AF4, AF9, AFF3, AKAP12, AKAP9,

ALEX3, ALK, ALOX15, APAF1, APC, ARHA, ARHGAP26, ARHGEF12, ARNT, ATBF1, ATF1, ATM, AXIN2, BCAS3, BCAS4, BCL1, BCL10, BCL11A, BCL11B, BCL2, BCL5, BCL7A, BCR, BIRC3, BMPR1A, BRCA2, BRD4, BRIP1, BTG1, BUB1B, CAGE-1, CARS, CASC5, CCDC6, CCND2, CCND3, CDH11, CDKN1B, CDKN2A, CDX2, CEP110, CKN1, CLP1, CLTC, CLTCL1, CNC, COL1A1, COX6C, CREBBP, CXXC6, DAB2IP, DDIT3, DDX43, DIRC1, DIRC2, DKK1, E2F3, EEN, EGFR, ELL, EPS15, ERBB2, ERC1, ERCC1, ERCC4, ERG, ETV1, ETV6, EVI1, EWSR1, EXT1, EXT2, FANCA, FANCD2, FANCF, FAS, FBP17, FCRL4, FEV, FGFR1, FHIT, FLI1, FOXO3A, FUS, FVT1, GAS7, GLI1, GNAS, GOLGA5, GOPC, GRB2, HCMOGT-1, HIST1H4I, HLF, HMGA2, HOXA13, HOXC11, HOXC13, HOXD13, HSP-BAP1, HSPCB, HSPD1, HSPH1, IKZF2, INTS6, IRF4, JAG1, JAG2, JAK2, JARID1A, JAZF1, JMJD2C, JUN, KIT, KITLG, KLF5, KLF6, LASP1, LDB1, LHFP, LMO1, LMO2, LPHN2, LPP, LYL1, MADH4, MAF, MAFB, MDM2, MDS2, MET, MKL1, MLF1, MLH1, MLL, MLLT10, MMP2, MN1, MRE11B, MSF, MSH2, MSH6, MSI2, MUC1, MUTYH, MXI1, MYC, MYH9, MYST3, NF1, NFKB1, NIN, NKX2-5, NONO, NOTCH1, N-RAS, NTRK3, NUMA1, NUP214, NUP98, OLIG2, P53, PALB2, PAX2, PAX5, PAX7, PAX9, PBX1, PCM1, PCSK7, PDGFB, PDGFRA, PDGFRB, PHOX2B, PICALM, PLAG1, PLCB1, PLK, PML, PMS1, POLH, POU5F1P1, POU6F2, PPP1R13L, PRDM16, PRRX1, PSIP1, PTCH, RABEP1, RAD51L1, RAD53, RANBP17, RAP1GDS1, RAP2B, RARA, RASSF1, RB1, RBL2, RBM15, RBM5, RCHY1, RECQL, RECQL5, RET, RUNX, RUNX1T1, SBDS, SDHC, SDHD, SET, SHH, SIL, SIX1, SNAI2, SPI1, SPINK7, STARD3, STAT3, STK11, STK4, SUFU, SYK, SYNPO2, TBX2, TCF3, THBS2, THRAP3, TMPRSS2, TNF, TOP1, TPM4, TPR, TRIM24, TRIM33, TRIP11, TSC1, TSC2, TSHR, TTL, VAV1, VHL, WFDC1, WT1, WWOX, XPC, ZBTB16, ZNF146 and ZNF217 can be recited. In addition to quantifying or detecting methylated DNA in the target DNA region individually, by using more target DNA regions in one detection system, for example, the quantification accuracy and detection sensitivity will improve accordingly.

[0136] The “target DNA region” may be a repetitive sequence interspersed in a genome. In particular, a methylation degree of a repetitive sequence that is apparently methylated by affection can be utilized as a surrogate marker of the disease. For example, in cancer, methylation of SINE and LINE is known, and concretely, subfamilies such as AluJb, AluJo, AluSc, AluSg, AluSg/x, AluSp, AluSq, AluSq/x, AluSx, AluY, FRAM, FLAM_A, MIR, MIRb, MIR3, L1Med, L1M4, L1M5, L1MA3, L1MA7, L1MA9, L1MC, L1MC2, L1MC4, L1MC4a, L1MC5, L1MDa, L1MD1, L1MD2, L1MEe, L1ME3A, L1PA15, L1PREC2, L2, L3, and HAL1 are known.

[0137] Repetitive sequences in a genome are generally classified into simple repetitive sequences (called a tandem repetitive sequence, or a tandem repeat) and interspersed repetitive sequences.

[0138] Simple repetitive sequences are characterized in that the same sequences neighbor in the same orientation, and for example, broadly classified into the following five kinds: (1) repetitive sequences in which a relatively short sequence such as CCA is repeated, (2) repetitive sequences derived from a transcription factor, (3) a series of repetitive sequences such as centromere, telomere, kinetochore, and ribosome

group genes, (4) inert processed pseudogenes reversely transferred from RNA or protein, and (5) gene sequences amplified by gene duplication.

[0139] First, as a repeat composed of a relatively short nucleotide sequence, sequences such as (A)_n, (T)_n, (GA)_n, (CA)_n, (TAA)_n, (GGA)_n, (CAGC)_n, (CATA)_n, (GAAA)_n, (TATG)_n, (TTTG)_n, (TTTA)_n, (TTTC)_n, (TAAA)_n, (TTCA)_n, (TATAA)_n, (TCTCC)_n, (TTTCC)_n, (TTTAA)_n, (TTTTC)_n, (TTTTA)_n, (TTTTG)_n, (CAAAA)_n, (CACCC)_n, (TATATG)_n, (CATATA)_n, (TCTCTG)_n, (AGGGGG)_n, (CCCCCA)_n, and (TGGGGG)_n (n means the number of repetition) are known. Next, as the sequence derived from a transcription factor, MER1-Charlie and Zaphod of hAT group, and MER2-Tigger, Tc-1 and Mariner of Tc-1 group are appropriate. As other repetitive sequences derived from a transcription factor on a genome, Tigger1, Tigger2a, Tigger5, Charlie4a, Charlie7 and the like are known. Since these repetitive sequences formed of a short nucleotide sequence, or repetitive sequences derived from a transcription factor are generally short and simple nucleotide sequences, setting of a specific oligonucleotide of the present method is difficult, however, if a practicable specific oligonucleotide can be set, these are not necessarily excluded as an object of the present method. Here, satellite DNA, minisatellite, microsatellite and the like are repetitive sequences that are classified into simple repetitive sequences.

[0140] As to a sequence that exists in multicopy in genes, if a specific oligonucleotide of the present method can be set for genes existing in multicopy in a genome as a result of gene duplication, as well as ALR6 as a sequence existing in centromere, U2 and U6 as snRNAs, and other genes that are known to exist in multicopy in a genome such as tRNA and rRNA, the detection sensitivity can be improved compared to detecting one gene in one genome.

[0141] It is also known that a retrovirus, a retrotransposon having LTR (Long terminal repeat) in its terminal, an endogenous sequence such as MaLRs (Mammalian apparent LTR-Retrotransposons) considered to be derived from viruses, and LTR derived from a retrovirus exist in multicopy in one genome.

[0142] For example, as the LTR derived from a retrovirus, concretely, subfamilies such as LTR1, LTR1B, LTR5, LTR7, LTR8, LTR16A1, LTR16A1, LTR16C, LTR26, LTR26E, MER48, and MLT2CB are known. The LTRs derived from a retrotransposon are classified into classes of ERV, ERVK and ERVL, and concrete examples include subfamilies such as LTR8A, LTR28, MER21B, MER83, MER31B, MER49, MER66B, HERVH, ERVL, LTR16A1, LTR33A, LTR50, LTR52, MLT2A1, MLT2E, MER11C, and MER11C. Further, MaLRs indicate DNA factors including LTRs in both ends likewise a typical retrotransposon, wherein an internal sequence sandwiched between LTRs is not derived from a retrovirus. For example, subfamilies such as MLT1A1, MLT1A2, MLT1B, MLT1C, MLT1D, MLT1E, MLT1G, MLT1H, MLT1J, MLT1K, MLT1I, MLT2CB, MSTA, MSTA-int, MSTB, THE1A, THE1B, THE1B-internal, and THE1 can be recited.

[0143] The interspersed repetitive sequences are characterized by being interspersed without neighboring each other, and are considered to be derived from a retrotransposon. Further, the interspersed repetitive sequences are classified into SINE (Short Interspersed Repetitive Element: short chain interspersed repetitive sequences) and LINE (Long Interspersed Elements: long-chain interspersed repetitive

sequences) according to the length. Most of SINES are sequences belonging to the Alu family. A common feature of the Alu family is that it has a sequence of 3'-side or a sequence of 5'-side of 7SL RNA, and that it has an AT-Rich region sandwiched between a Left-monomer and a Right-monomer. As subfamilies of the Alu family, Alu, AluJb, AluJo, AluSc, AluSg, AluSp, AluSq, AluSx, AluY, and FAM (Fossil Alu Monomer), FLAM (Free Left Alu Monomer) having a sequence of FAM, and FRAM (Free Right Alu Monomer) can be recited. As SINES other than the Alu family, MIR, and Ther/MIR3 are known, and MIR and MIR3 are known as respective subfamilies. As subfamilies of the Alu family including other biological species than human being, B1, B2, B4, PB1, PB1D and so on are known. As LINEs, subfamilies of LINE1 to Line23 are reported, and it is known that subfamilies such as LINE-1, LINE2, and LINE3 broadly exist in a genome. As for LINE-1, for example, L1M1, L1M2, L1M3, L1M3d, L1M4, L1M4c, L1MA2, L1MA7, L1MA8, L1MA9, L1MB1, L1MB1, L1MB3, L1MB4, L1MB5, L1MB6, L1MB7, L1MCa, L1MCb, L1MC2, L1MC3, L1MC4, L1MC4a, L1MC5, L1MDa, L1ME, L1MEc, L1MEd, L1MEg, L1ME1, L1ME2, L1ME3, L1ME3A, L1ME3B, L1ME4a, L1PB3, L1P4, L1PA2, L1PA3, L1PA4, L1PA5, L1PA6, L1PA7, L1PA10, L1PA12, L1PA13, L1PA14, L1PA16, L1PB1, L1PB3, L1PB4, L1PREC2, and HAL1 are known, and as LINE-2, subfamilies such as L2 and L2c are known.

[0144] Among these repetitive sequences interspersed in a genome, the one that will be methylated by affection can be utilized as a highly sensitive detection system as a surrogate marker of the disease by the present method.

[0145] The term quantification in "quantify or detect DNA" is estimation of methylation frequency or an index value correlated therewith in the target DNA region in the specimen, from the quantified methylated DNA antibody, and means methylation frequency or an index value correlated therewith of DNA of the target region contained in 1 mL of serum when the specimen is 1 mL of serum.

[0146] The term "detect" in "quantify or detect DNA" means that whether methylated DNA exists in the target DNA region can be distinguished from whether the methylated DNA antibody is detected or not, and represents that methylated DNA exists in the target DNA region in the specimen when the methylated DNA antibody is detected, and represents that the abundance of methylated DNA in the target DNA region in the specimen is less than a detection limit when the methylated DNA antibody or the specific oligonucleotide is not detected.

[0147] In First step, double-stranded DNA derived from genomic DNA that comprises the target DNA region and is contained in the biological specimen is temporarily separated into a single-stranded state. Concretely, for example, by adding an annealing buffer to the double-stranded DNA, a mixture is obtained. Next, the obtained mixture is boiled at 95° C. for about 30 seconds, and then rapidly cooled on ice chilled water for several minutes. For example, free DNA contained in blood or the like can be single-stranded DNA. Therefore, when genomic DNA contained in the biological specimen is single-stranded DNA, this operation is not required.

[0148] The term "methylated DNA antibody" in Second step means an antibody that binds with a methylated base in DNA as an antigen. More desirably, it is an antibody that has a property of binding by recognition of cytosine whose 5-position is methylated in single-stranded DNA, and more con-

cretely it may be the methylcytosine antibody. Also a commercially available methylated DNA antibody capable of specifically recognizing DNA in a methylation state described in the present invention and specifically binding thereto is applicable. The methylated DNA antibody may be produced by a usual method from a methylated base, methylated DNA or the like as an antigen. Concretely, it may be produced by selection according to the specific binding to methylcytosine in DNA as an index, from antibodies generated by using 5-methylcytidine, 5-methylcytosine, or DNA and the like containing 5-methylcytosine as an antigen. As antibodies that can be obtained by immunizing an animal with an antigen, a method using an antibody of IgG fraction (polyclonal antibody) following immunization with a purified antigen and a method using an antibody producing a single clone (monoclonal antibody) are known. In the present invention, since an antibody capable of specifically recognizing methylated DNA or methylcytosine is desired, use of a monoclonal antibody is desired.

[0149] As a method of preparing a monoclonal antibody, a procedure based on a cell fusion method can be recited. For example, in the cell fusion method, a hybridoma is prepared by allowing cell fusion between a spleen cell (B cell) derived from an immunized mouse and a myeloma cell, and an antibody produced by the hybridoma is selected for preparation of a methyl cytosine antibody (monoclonal antibody). When a monoclonal antibody is prepared by a cell fusion method, it is not necessary to purify an antigen, and for example, a mixture of 5-methyl cytidine, 5-methyl cytosine or DNA or the like containing 5-methyl cytosine may be administered as an antigen to an animal used for immunization. As an administration method, 5-methyl cytidine, 5-methyl cytosine or DNA or the like containing 5-methyl cytosine is directly administered to a mouse for production of an antibody. When an antibody is difficult to be produced, an antigen bound to a support may be used for immunization. Also, by thoroughly mixing an adjuvant solution (prepared, for example, by mixing liquid paraffin and Aracel A, and mixing killed tubercle bacilli as an adjuvant) and an antigen, and immunizing via liposome incorporating the same, immunity of an antigen can be improved. Also a method involving adding equivalent amounts of a solution containing an antigen and an adjuvant solution, fully emulsifying them, and subcutaneously or intraperitoneally injecting the resultant mixture to a mouse, and a method of adding killed *Bordetella pertussis* as an adjuvant after mixing well with alum water are known. A mouse may be boosted intraperitoneally or intravenously after an appropriate term from initial immunization. When the amount of an antigen is small, a solution in which the antigen is suspended may be directly injected into a mouse spleen to effect immunization.

[0150] After exenterating a spleen and peeling an adipose tissue off after several days from the final immunization, a spleen cell suspension is prepared. The spleen cell is fused, for example, with an HGPRT-deficient myeloma cell to prepare a hybridoma. As a cell fusion agent, any means capable of efficiently fusing a spleen cell (B cell) and a myeloma cell is applicable, and for example, a method of using a hemagglutinating virus of Japan (HVJ), polyethyleneglycol (PEG) and the like are recited. Cell fusion may be conducted by a method using a high voltage pulse.

[0151] After the cell fusion operation, cells are cultured in an HAT medium, a clone of a hybridoma in which a spleen cell and a myeloma cell are fused is selected, and the cell is

allowed to grow until screening becomes possible. In a method of detecting an antibody for selecting a hybridoma that produces an intended antibody, or a method of measuring a titer of an antibody, an antigen-antibody reaction system may be used. Concretely, as a method of measuring an antibody against a soluble antigen, a radioisotope immune assay (RIA), an enzyme-linked immunosorbent assay (ELISA) and the like can be recited.

[0152] Considering the property of the methylated DNA antibody (one antibody binds to one methylated base (cytosine)), it is desired to select a region where a number of methylated bases (cytosine), namely CpG are present as a target DNA region, and thus an improvement in quantification accuracy and detection sensitivity is expected.

[0153] The term "specific oligonucleotide" means an oligonucleotide comprising a nucleotide sequence capable of base-pairing with single-stranded DNA containing the target DNA region, and not inhibiting binding of the methylated DNA antibody to a methylated base (cytosine) in single-stranded DNA containing the target DNA region in base-pairing with single-stranded DNA containing the target DNA region. In other words, it is an oligonucleotide that will not inhibit binding between the methylated base in the target DNA region in single-stranded DNA and the methylated DNA antibody. More concretely, it is, for example, an oligonucleotide that will not inhibit binding between methylcytosine in the target DNA region and the methylcytosine antibody, and is capable of binding with single-stranded DNA containing the target DNA region by complementation.

[0154] The wording "nucleotide sequence capable of binding with single-stranded DNA containing the target DNA region" means a nucleotide sequence required for forming a bound body (double strand) with single-stranded DNA containing the target DNA region, namely, a nucleotide sequence containing a nucleotide sequence complementary to a part of the nucleotide sequence of the target DNA region, or a nucleotide sequence containing a nucleotide sequence complementary to a part of a nucleotide sequence of a DNA region on a further 5'-end side than 5'-end of the target DNA region, or a nucleotide sequence containing a nucleotide sequence complementary to a part of a nucleotide sequence of a DNA region on a further 3'-end side than 3'-end of the target DNA region. The wording "not inhibiting binding of the methylated DNA antibody to a methylated base (cytosine) in the single-stranded DNA containing the target DNA region" means that the nucleotide sequence of the specific oligonucleotide is such a nucleotide sequence that complementarily binding between the specific oligonucleotide and the single-stranded DNA will not occur in an occupied space required for binding of the methylated DNA antibody with methylated single-stranded DNA. That is, it is supposed that for the methylated DNA antibody to bind with the methylated base (cytosine), not only the directly binding methylated base (cytosine), but also a peripheral space where the methylated base (cytosine) exists is also occupied. Therefore, the specific oligonucleotide should be the one that fails to complementarily bind with the single-stranded DNA in the occupied space required for the methylated DNA antibody in binding with the methylated DNA.

[0155] The present invention enables simultaneous detection of at least one target DNA region using at least one specific oligonucleotide. That is, the specific oligonucleotide to be bound to the single-stranded DNA is not necessarily one kind, but two or more kinds may be used unless binding of the

methylated DNA antibody is inhibited. By using plural kinds of specific oligonucleotides, it is possible to improve the quantification accuracy and detection accuracy. Further, by detecting plural target regions simultaneously, it is possible to increase the amount of methylated DNA to be measured.

[0156] As concrete examples of the “specific oligonucleotide”, a nucleotide sequence of any of SEQ ID NOs: 13 to 24, and complementary sequences thereof can be recited, or nucleotide sequences having a sequence identity of 80% or more, 90% or more, 95% or more, or 98% or more with such nucleotide sequences are also recited.

[0157] In Second step, as a preferred form in forming the complex of the single-stranded DNA, the methylated DNA antibody, and the specific oligonucleotide, formation in a reaction system containing a divalent cation is recited. More preferably, the divalent cation is a magnesium ion. Here, the “reaction system containing a divalent cation” means such a reaction system that a divalent cation is contained in an annealing buffer used for binding between the single-stranded DNA containing the target DNA region and the specific oligonucleotide, and concretely, for example, a salt composed of a magnesium ion (for example, $MgOAc_2$, $MgCl_2$ or the like) may be contained in a concentration of 1 mM to 600 mM.

[0158] Besides this, in Second step, as a preferred form in forming the complex of the single-stranded DNA, the methylated DNA antibody and the specific oligonucleotide, a counter oligonucleotide may be added. The counter oligonucleotide is obtained by dividing the same nucleotide sequence as the target DNA region into short oligonucleotides. It may be designed to have usually 10 to 100 bases, and more preferably 20 to 50 bases. The counter oligonucleotide is not designed on the nucleotide sequence where the specific oligonucleotide and the target region bind. The counter oligonucleotide is added in large excess with respect to genomic DNA, and is added for preventing a complementary strand (minus strand) of the target DNA region and a single strand (plus strand) of the target DNA region from rebinding by complementation in causing binding with the specific oligonucleotide (minus strand) after making the target DNA region into the single strand (plus strand). This is because in causing binding of the methylated DNA antibody with the target DNA region, and measuring methylation frequency of DNA and an index value correlated therewith, the target region in a single strand state is more likely to bind with the methylated DNA antibody. The counter oligonucleotide is preferably added in an amount of at least 10 times, and usually 100 times or more compared to the target DNA region.

[0159] The wording “formation of a complex” means a mixture in such a condition that the single-stranded DNA containing the methylated target DNA region, the specific oligonucleotide, and the methylated DNA antibody bind. In the present invention, it is preferred to immobilize the complex to a support by binding the methylated DNA antibody or the specific oligonucleotide in the complex with the support before Third step to be described later.

[0160] The material and form of the support are not particularly limited as far as a complex can bind thereto. For example, any form suited for use purpose may be employed, including the forms of tube, test plate, filter, disc, bead and so on. As the material, those used as supports for a usual immune measuring method, for example, synthetic resins such as polystyrene, polypropylene, polyacrylamide, polymethylmethacrylate, polysulfone, polyacrylonitrile and nylon, or the

synthetic resins incorporating a reactive functional group such as a sulfonic group, or an amino group can be recited. Also, glass, polysaccharides or derivatives thereof (cellulose, nitrocellulose and so on), silica gel, porous ceramics, metal oxides and the like may be used.

[0161] As a method of immobilizing the complex to the support by binding, a method of immobilizing the specific oligonucleotide to the support is recited. For binding the single-stranded DNA containing the methylated target DNA region to the support via the specific oligonucleotide, the methylated DNA antibody is quantified or detected by its identification function (to be described later).

[0162] For allowing the specific oligonucleotide to be immobilized to the support, the specific oligonucleotide may be immobilized to the support eventually in the condition that the single-stranded DNA containing the methylated target DNA region and the methylated DNA antibody form a complex, and (1) the specific oligonucleotide may be immobilized to the support in the stage before binding of the single-stranded DNA and the specific oligonucleotide, or (2) the specific oligonucleotide may be immobilized to the support in the stage after binding of the single-stranded DNA and the specific oligonucleotide.

[0163] For immobilizing a specific oligonucleotide to a support, concretely a method of immobilizing a biotinylated oligonucleotide obtained by biotinylating 5'-end or 3'-end of the specific oligonucleotide to a support coated with streptavidin (for example, a PCR tube coated with streptavidin, magnetic beads coated with streptavidin, a chromatostrip partially coated with streptavidin, or the like) is recited.

[0164] Also there is a method of letting 5'-end or 3'-end of a specific oligonucleotide covalently bind with a molecule having an active functional group such as an amino group, a thiol group, or an aldehyde group, and then letting it covalently bind to a support made of glass, a polysaccharide derivative, silica gel, the synthetic resin or thermostable plastic whose surface is activated by a silane coupling agent or the like. Covalent binding is achieved, for example, by a spacer formed by serially connecting five triglycerides, a cross linker or the like. Also there is a method of chemical synthesis from the terminal side of the specific oligonucleotide directly on a support of glass or silicon.

[0165] Other concrete methods may be practiced in the following manners, using “biotinylated specific oligonucleotide” whose terminal end is labeled with biotin as a specific oligonucleotide that is immobilizable to a support. (a) A mixture is obtained by adding an annealing buffer (for example, 33 mM Tris-Acetate pH 7.9, 66 mM KOAc, 10 mM $MgOAc_2$, 0.5 mM Dithiothreitol) and a biotinylated specific oligonucleotide to the DNA sample derived from genomic DNA contained in the biological specimen. Then the obtained mixture is heated at 95° C., for example, for several minutes to make double-stranded DNA derived from genomic DNA contained in the biological specimen into single-stranded DNA. Then the mixture is rapidly cooled to a temperature that is lower than the T_m value of the biotinylated specific oligonucleotide by about 10 to 20° C., and kept at this temperature, for example, for several minutes, and then the temperature is returned to room temperature for allowing formation of a bound body between the single-stranded DNA containing the target DNA region and the biotinylated specific oligonucleotide (the bound body formed in this stage includes a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide, as

well as a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide). (b) By adding the mixture obtained in the above (a) to a support coated with streptavidin, and retaining it at 37° C. for example, for several minutes, the bound body between the single-stranded DNA containing the target DNA region and the biotinylated specific oligonucleotide is immobilized to the support coated with streptavidin. Thereafter, the remaining solution is removed and washing is performed. A washing buffer (for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl pH 7.4)) is added, for example, in a proportion of 300 μL /well, and the solution is removed. This washing operation is repeated several times, to leave the bound body between the biotinylated specific oligonucleotide immobilized to the support, and the single-stranded DNA containing the target DNA region, on the well (also in this stage, the bound body formed in this state includes a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide, as well as a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide).

[0166] (c) An appropriate amount (for example, 100 μL /well of a 4 $\mu\text{g}/\text{mL}$ solution) of a methylated DNA antibody is added to the well, and then left still at room temperature, for example, for about 3 hours, to promote formation of a complex of the methylated DNA antibody, single-stranded DNA containing the methylated target DNA region, of the single-stranded DNA, and the biotinylated specific oligonucleotide (formation of a complex) (in this stage, the bound body between the single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex). Thereafter, the remaining solution is removed and washing is performed. A washing buffer (for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl pH 7.4)) is added, for example, in a proportion of 300 μL /well, and the solution is removed. This washing operation is repeated several times, to leave the complex on the well (selection of a complex).

[0167] The annealing buffer used in (a) is not limited to the annealing buffer described above as far as it is suited for binding between the specific oligonucleotide and single-stranded DNA containing the target DNA region derived from a biological sample. Use of a buffer in which a divalent ion, preferably a magnesium ion is dissolved in a concentration of 1 to 600 mM will improve the binding stability.

[0168] The washing operation in (b) and (c) is important for removing the methylated DNA antibody that is not immobilized and suspended in the solution, single-stranded DNA that is not bound to the methylated DNA antibody and suspended in the solution, or DNA that has been digested with a restriction enzyme to be described later and suspended in the solution, from the reaction solution. The washing buffer is not limited to the washing buffer described above, insofar as it is suited for removing the free methylated DNA antibody, single-stranded DNA and so on suspended in the solution, and a DELFIA buffer (available from PerkinElmer, Tris-HCl pH 7.8 with Tween 80), a TE buffer and the like may be used.

[0169] As described above, in the above (a) to (c), binding between single-stranded DNA containing the target DNA region and the biotinylated specific oligonucleotide is conducted in the stage previous to the immobilization of the

biotinylated specific oligonucleotide to the support coated with streptavidin, however, this order may be inverted. In other words, for example, a mixture is obtained by adding the DNA sample derived from genomic DNA contained in the biological specimen to the biotinylated specific oligonucleotide immobilized to the support coated with streptavidin. For making double-stranded DNA containing the target DNA region possessed by genomic DNA contained in the biological specimen into a single strand, the obtained mixture is heated at 95° C., for example, for several minutes, and then for allowing formation of a bound body with the biotinylated specific oligonucleotide, the reaction is rapidly cooled to a temperature lower than the T_m value of the biotinylated specific oligonucleotide by about 10 to 20° C., and retained at this temperature, for example, for several minutes (the bound body formed in this stage includes a bound body between methylated single-stranded DNA other than the target DNA region and the methylated antibody, as well as a bound body between single-stranded DNA containing the methylated target DNA region and the methylated antibody). Thereafter, the operation of (c) may be practiced, to form and select a complex (in this stage, a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex).

[0170] The operations of the above (a) to (c) may be conducted using a chromatostrip. In this case, the operation is conducted in the following manner. The solution in which the bound body between the single-stranded DNA containing the target DNA region possessed by genomic DNA contained in the biological specimen and the biotinylated specific oligonucleotide is formed is developed by a chromatostrip partially coated with streptavidin. By this operation, the bound body between the single-stranded DNA containing the target DNA region possessed by genomic DNA contained in the biological specimen and the biotinylated specific oligonucleotide is immobilized to the part coated with streptavidin (the bound body formed in this stage includes a bound body between methylated single-stranded DNA other than the target DNA region and the methylated antibody, as well as a bound body between single-stranded DNA containing the methylated target DNA region and the methylated antibody). Then an appropriate amount of the methylated DNA antibody is developed by a chromatostrip as described above. Through these operations, the complex of single-stranded DNA containing the methylated target DNA region possessed by genomic DNA contained the biological specimen, the biotinylated specific oligonucleotide, and the methylated DNA antibody is immobilized to the part coated with streptavidin (formation and selection of a complex) (in this stage, the bound body between the single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex). Also for these operations, the order of formation of a complex may be inverted. For example, after forming a complex made up of single-stranded DNA containing the methylated target DNA region, a biotinylated specific oligonucleotide, and a methylated DNA antibody, the complex may be developed by a chromatostrip, and immobilized to the part coated with streptavidin. In these operations, unnecessary components can be removed by developing the solution by a chromatostrip, and a washing operation can be omitted. Of course, a washing operation (development of a chromatostrip by a washing buffer (for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3

mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4))) may be conducted between operations without causing any problem.

[0171] The “identification function” in Third step is a function based on labeling used for detection or quantification, and concretely, in the case of a methylated DNA antibody, a fluorescent or a chromogenic property of a label in a methylated DNA antibody labeled with europium, gold colloid, latex beads, a radioisotope, a fluorescent substance (FITC or the like), horseradish Peroxidase (HRP), alkaline phosphatase, biotin or the like can be recited, and the property that the antibody itself binds to a secondary antibody and the like are also recited as the function. As a means for quantifying or detecting such a function, for example, measurement by a radiation detector or a spectrophotometer, or visual check may be used.

[0172] In the case of a methylated DNA antibody, as described above, the property that the antibody itself binds to a secondary antibody or the like is considered as the function. That is, even when the antibody itself is not labeled, a methylated DNA antibody can be indirectly quantified or detected by using a secondary antibody to which the quantifiable or detectable recognition function is imparted.

[0173] When a methylated DNA antibody is quantified or detected depending on its identification function, concretely, when the property of the antibody itself is used as the function, the operation may be conducted in the following manner. A secondary antibody against a methylated DNA antibody (for example, an Eu-N1-labeled mouse IgG antibody: available from PerkinElmer) is added to a complex, and left still at room temperature for about an hour, to promote binding of the secondary antibody to the complex. Then, Enhancement Solution (available from PerkinElmer) is added and mixed, and left still, for example, for about 45 minutes at room temperature. Thereafter, the fluorescence (excitation 340 nm/fluorescence 612 nm) is measured by a fluorescence detector to quantify or detect the methylated DNA antibody. When an antibody to which FITC is bound is used as a secondary antibody, the methylated DNA antibody may be quantified or detected by measuring fluorescence of FITC by a known method. For example, when biotin is not used for immobilization of the specific oligonucleotide, a biotinylated methylated DNA antibody may be used for quantification or detection. When the biotinylated methylated DNA antibody is quantified or detected, a biotinylated methylated DNA antibody can be quantified or detected, for example, by adding and mixing HRP-labeled streptavidin with the biotinylated methylated DNA antibody, and measuring the activity of HRP by a known method after formation of a bound body between the biotinylated methylated DNA antibody and HRP-labeled streptavidin.

[0174] The present invention includes a modified method (Modified method 1) additionally comprising a step of digesting unmethylated single-stranded DNA by a methylation sensitive restriction enzyme capable of digesting single-stranded DNA after First step and before Third step, and a modified method (Modified method 2) additionally comprising a step of digesting an unmethylated single-stranded DNA by a methylation sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide comprising a recognition sequence for the methylation sensitive restriction enzyme as its part after First step and before Third step of the present invention.

[0175] The “methylation sensitive restriction enzyme” in these modified methods (Modified method 1 and Modified

method 2) means, for example, a restriction enzyme or the like that fails to digest a recognition sequence containing methylated cytosine, but digests only a recognition sequence containing unmethylated cytosine. In other words, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is methylated, the DNA will not be cleaved even when the methylation sensitive restriction enzyme is caused to act on the DNA. On the other hand, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is not methylated, the DNA will be cleaved when the methylation sensitive restriction enzyme is caused to act on the DNA. Concrete examples of such methylation sensitive enzymes include HpaII, BstUI, NarI, SacII, and HhaI. The methylation sensitive restriction enzyme fails to cleave double-stranded DNA in a hemimethyl state (double-stranded DNA wherein cytosine (CpG) in one strand is methylated, and complementary cytosine (CpG) in the other strand is not methylated), and this is already revealed by Gruenbaum et al. (Nucleic Acid Research, 9, 2509-2515).

[0176] The wording “methylation sensitive restriction enzyme capable of digesting single-stranded DNA” means, for example, a restriction enzyme or the like capable of digesting only a recognition sequence containing unmethylated cytosine without digesting a recognition sequence containing methylated cytosine in single-stranded DNA. In other words, some methylation sensitive restriction enzymes digest single-stranded DNA. For example, HhaI or the like is recited.

[0177] As a fear in a digestion treatment with a methylation sensitive restriction enzyme, the possibility that the recognition sequence containing unmethylated cytosine may not be completely digested (so called “DNA remaining undigested”) is recited. When such a possibility is problematic, the target DNA region has at least one recognition site of a methylation sensitive restriction enzyme, and as many as possible recognition sites would be preferred because it is possible to suppress the “DNA remaining undigested” as much as possible by presence of abundant recognition sites of a methylation sensitive restriction enzyme.

[0178] As described above, as to the target DNA region, from the viewpoint of the property of the methylated DNA antibody (one antibody binds to one methylated base (cytosine)), a region where a number of methylated bases (cytosine, CpG) exist is desirably selected as a target DNA region, and from the viewpoint of minimizing “DNA remaining undigested”, a region where a number of recognition sites of a methylation sensitive restriction enzyme exist is desirably selected.

[0179] The term “specific masking oligonucleotide” in Modified method 2 means an oligonucleotide comprising a recognition sequence for a methylation sensitive restriction enzyme as its part. Concretely, it is an oligonucleotide that forms double-stranded DNA by complementary binding with one specific site (one or more sites may be concurrently contained in the following 8 to 30 bases depending on the nucleotide sequence of the target region) of several recognition sequences of a methylation sensitive restriction enzyme contained in the target DNA region in single-stranded DNA (namely, the site is made into a double-stranded state), thereby enabling the methylation sensitive restriction enzyme that uses only double-stranded DNA as a substrate to digest the site, and improving digestion efficiency at the site for the

methylation sensitive restriction enzyme capable of digesting single-stranded DNA (the methylation sensitive restriction enzyme capable of digesting single-stranded DNA also digests double-stranded DNA, and digestion efficiency thereof is higher for double-stranded DNA than for single-stranded DNA), and is a nucleotide not inhibiting formation of a bound body between single-stranded DNA containing DNA of a target region and the specific oligonucleotide.

[0180] As the specific masking oligonucleotide, more concretely, oligonucleotides comprising a nucleotide sequence complementary to a nucleotide sequence having a length of 8 to 30 bases containing one specific site (one or more sites may be concurrently contained in the following 8 to 30 bases depending on the nucleotide sequence of the target) among several recognition sequences of the methylation sensitive restriction enzyme contained in the target DNA region in single-stranded DNA, and not inhibiting formation of the bound body between the single-stranded DNA containing DNA of the target region and the specific oligonucleotide can be recited.

[0181] The specific masking oligonucleotide to be mixed with the DNA sample derived from genomic DNA may be one kind or plural kinds. When plural kinds are used, many of recognition sites of the methylation sensitive restriction enzyme in single-stranded DNA containing a target DNA region become a double-stranded DNA state, and "DNA remaining undigested" as described above by a methylation sensitive restriction enzyme can be minimized. However, since the methylated DNA antibody is no longer able to bind to the site where the specific masking oligonucleotide forms double-stranded DNA, it is not appropriate to use the specific masking oligonucleotide for too many recognition sites of the methylation sensitive restriction enzyme, and it is preferred to use appropriate kinds. If the specific masking oligonucleotide is used for every recognition site of the methylation sensitive restriction enzyme contained in the target DNA region, binding between a methylated base (cytosine) and the methylated DNA antibody in the recognition site is inhibited, and the probability of formation of a complex comprising a methylated target DNA region can be decreased (of course, the methylated DNA antibody binds to CpG other than the recognition site, however, when the methylated DNA antibody is quantified or detected, the quantification accuracy and the detection sensitivity are decreased). For example, it is particularly useful to use the specific masking oligonucleotide designed for the site where it is necessarily intended not to be digested when it is methylated and intended to be digested when it is not methylated among several recognition sequences of the methylation sensitive restriction enzyme contained in the target DNA region (for example, the site that is methylated at 100% in an affected diseased patient specimen, but is not methylated at 100% in a healthy subject specimen).

[0182] In these Modified methods (Modified method 1 and Modified method 2), by conducting the step of digesting by at least one kind of methylation sensitive restriction enzyme after First step and before Third step, it is possible to minimize (exclude) formation of a complex comprising an unmethylated target DNA region, so that the quantification accuracy and the detection sensitivity of methylated DNA in the target DNA region are improved.

[0183] In Modified method 1, the operation of digesting the single-stranded DNA obtained in First step by at least one kind of methylation sensitive restriction enzyme capable of

digesting single-stranded DNA executed after end of First step and before start of Third step may be concretely executed in the following manner. To 10 μL of a specimen solution containing single-stranded DNA obtained in First step, 3 μL of an optimum 10 \times buffer, 15 U of a methylation sensitive enzyme (HhaI) capable of digesting a single strand, and an appropriate amount of BSA or the like as necessary are added, and then the resultant mixture is added with sterile ultrapure water to a liquid volume of 30 μL , and then incubated at 37 $^{\circ}$ C., for example, for an hour to overnight. As a result, the HhaI recognition site unmethylated in the target DNA region will be digested (a treatment solution). For example, when this operation is conducted before formation of a complex, the treatment solution may be directly used for formation of a complex because a washing operation is executed at the time of formation of a complex and (or) selection. When this operation is conducted after selection of a complex, since it is necessary to remove single-stranded DNA (digested and generated single-stranded DNA because the recognition site of the methylation sensitive restriction enzyme is not methylated) suspended in the treatment solution from the treatment solution, it is necessary to conduct a washing operation similar to that executed in formation of a complex and (or) selection again after end of this operation.

[0184] In Modified method 2, the operation of conducting a digestion treatment by adding the single-stranded DNA obtained in First step, with at least one kind of methylation sensitive restriction enzyme and the specific masking oligonucleotide comprising a recognition sequence for the methylation sensitive restriction enzyme as its part, after end of First step and before start of Third step, may be concretely conducted, for example, in the following manner. To 10 μL of a specimen solution containing single-stranded DNA obtained in First step, 3 μL of an optimum 10 \times buffer, 15 U of a methylation sensitive enzyme (HhaI, HhaI or the like), about 10 pmol of the specific masking oligonucleotide for one specific site among recognition sequences of the methylation sensitive enzyme, and an appropriate amount of BSA or the like as necessary are added, and then the resultant mixture is added with sterile ultrapure water to a liquid volume of 30 μL , and then incubated at 37 $^{\circ}$ C., for example, for an hour to overnight. As a result, the site unmethylated in the target DNA region will be digested (a treatment solution). For example, when this operation is conducted before formation of a complex, the treatment solution may be directly used for formation of a complex because the washing operation is conducted at the time of formation of a complex and (or) selection. When this operation is conducted after selection of a complex, since it is necessary to remove single-stranded DNA (digested and generated single-stranded DNA because a recognition site of the methylation sensitive restriction enzyme is not methylated) suspended in the treatment solution from the treatment solution, it is necessary to conduct a washing operation similar to that executed in formation of a complex and (or) selection again after end of this operation.

[0185] In the present invention, in one preferred embodiment, "a DNA sample derived from genomic DNA contained in the biological specimen" is a DNA sample that is preliminarily digested with a restriction enzyme recognition cleaving site for which is not present in the target DNA region of the genomic DNA. In forming a bound body between single-stranded DNA containing the target DNA region possessed by genomic DNA contained in the biological specimen and the specific oligonucleotide, it is expected that the shorter the

single-stranded DNA is, the better the operability is and the more easily a complex is formed as far as the target DNA region is contained. To shorten the single-stranded DNA, it is efficient to make it short when it is in former genomic DNA. Therefore, a digestion treatment may be preliminarily conducted using a restriction enzyme recognition cleaving site for which is not present in the target DNA region on a DNA sample derived from genomic DNA contained in the biological specimen. As a method of the digestion treatment by the restriction enzyme whose recognition cleaving site is not present in the target DNA region, a generally known restriction enzyme treatment method may be used. When the specimen is a DNA sample preliminarily purified, a digestion treatment may be executed using a generally used amount of a restriction enzyme, whereas when the specimen is a tissue lysate, a cell lysate or the like, a digestion treatment may be conducted using a large excess of a methylation sensitive restriction enzyme, for example, an amount of 500 times or more the DNA amount of a restriction enzyme.

[0186] In one preferred embodiment, "a DNA sample derived from genomic DNA contained in the biological specimen" is a DNA sample that has been digested with at least one kind of methylation sensitive restriction enzyme. By preliminarily digesting a biological specimen itself with a methylation sensitive restriction enzyme, it is possible to quantify or detect methylation at high accuracy in Final step. This method is useful for eliminating "DNA remaining undigested" as described above. As a method of digesting the specimen itself with a methylation sensitive restriction enzyme, when genomic DNA in the specimen exists in a state of double-stranded DNA, a generally known restriction enzyme treatment may be conducted using a methylation sensitive restriction enzyme. On the other hand, when genomic DNA in the specimen exists in a state of single-stranded DNA or when genomic DNA in the specimen exists in combined states of double-stranded DNA and single-stranded DNA, a digestion treatment may be conducted by the method corresponding to Modified method 1 or Modified method 2. Concretely, for example, to 10 μL of a specimen solution, 5 μL of an optimum 10 \times buffer, 15 U of a methylation sensitive restriction enzyme (HhaI) capable of digesting single-stranded DNA, and an appropriate amount of BSA or the like as necessary are added, and then the resultant mixture is added with sterile ultrapure water to a liquid volume of 50 μL , and then incubated at 37 $^{\circ}$ C., for example, for an hour to overnight. Alternatively, to 10 μL of a specimen, 5 μL of an optimum 10 \times buffer, 15 U of a methylation sensitive restriction enzyme (HpaII, HhaI or the like), about 15 pmol of a specific masking oligonucleotide for one specific site among recognition sequences of the methylation sensitive enzyme, and an appropriate amount of BSA or the like as necessary are added and then the resultant mixture is added with sterile ultrapure water to a liquid volume of 50 μL , and then incubated at 37 $^{\circ}$ C., for example, for an hour to overnight. When the specimen is a preliminarily purified DNA sample, the treatment may be executed using a generally used amount of a restriction enzyme, whereas when the specimen is a tissue lysate, a cell lysate or the like, the treatment may be conducted using a large excess of a methylation sensitive restriction enzyme, for example, an amount of 500 times or more the DNA amount of a methylation sensitive restriction enzyme.

[0187] As a method of quantifying or detecting minor substances contained in a biological sample such as blood or urine, immunological measuring methods are generally used.

Among such methods, a so-called immunochromatography using chromatography is widely used in various situations including, for example, clinical examinations in hospitals, assays in laboratories and so on because of its simple operation and short time required for assay. In recent years, a so-called hybrid chromatography has been utilized in which labeled DNA (gene) is developed on a chromatostrip, and target DNA (gene) is detected by hybridization using a probe capable of capturing the target DNA (gene). Also this method is now coming to be widely used in situations including, for example, clinical examinations in hospitals, assays in laboratories and so on because of its simple operation and short time required for assay. The present invention conceptually enables a combined method of the immunochromatography and the hybrid chromatography. In the present invention, since the order of formation of a complex and selection of a complex is not particularly limited, various methods are possible. Concretely, such methods may be executed in the following manner.

[0188] Method 1: A sample after end of First step is added with the biotinylated specific oligonucleotide, to cause formation of a bound body between single-stranded DNA containing the target DNA region and the biotinylated specific oligonucleotide (the bound body formed in this stage includes not only a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide, but also a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide), and added with a methylated antibody having the function, to cause formation of a complex of the single-stranded DNA containing the methylated target DNA region, the biotinylated specific oligonucleotide, and a methylated DNA antibody having the function (in this stage, the bound body between the single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex). Upon dropping (introduction) of the obtained sample into an introduction part of a chromatostrip, the complex migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin. Thereafter, by quantifying or detecting the methylated DNA antibody forming the obtained complex according to its function, methylated DNA in the target DNA region can be quantified or detected.

[0189] Method 2: A sample after end of First step is added with the biotinylated specific oligonucleotide, to cause formation of a bound body between single-stranded DNA containing the target DNA region and the biotinylated specific oligonucleotide (the bound body formed in this stage includes not only a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide, but also a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide). Upon dropping (introduction) of the obtained sample into an introduction part of a chromatostrip, the bound body migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin (also in this stage, the bound body includes not only a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide, but also a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide). Then, upon dropping (introduction) of a methylated antibody hav-

ing the function into an introduction part, it migrates in a development part and binds to methylated cytosine of the bound body, to form a complex of single-stranded DNA containing the methylated target DNA region, the biotinylated specific oligonucleotide, and a methylated DNA antibody having the function (in this stage, the bound body between the single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex). By quantifying or detecting a methylated DNA antibody contained in the obtained complex according to its function, methylated DNA in the target DNA region can be quantified or detected.

[0190] Method 3: Upon dropping (introduction) of the biotinylated specific oligonucleotide into an introduction part of a chromatostrip, the oligonucleotide migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin. Then, upon dropping (introduction) of a sample after end of First step into an introduction part, it migrates in a development part, and is trapped by the biotinylated specific oligonucleotide that has been already trapped in the condition that single-stranded DNA containing the target DNA region forms a bound body (the bound body formed in this stage includes not only a bound body between single-stranded DNA containing the methylated target DNA region and the specific oligonucleotide, but also a bound body between single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide). Then, upon dropping (introduction) of a methylated antibody having the function into an introduction part, it migrates in a development part, and binds to methylated cytosine of the bound body, to form a complex of single-stranded DNA containing the methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having the function (in this stage, the bound body between the single-stranded DNA containing an unmethylated target DNA region and the specific oligonucleotide fails to form a complex). By quantifying or detecting the methylated DNA antibody forming the obtained complex according to its function, methylated DNA in the target DNA region can be quantified or detected.

[0191] Method 4: Upon dropping (introduction) of the biotinylated specific oligonucleotide into an introduction part of a chromatostrip, the oligonucleotide migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin. A sample after end of First step is added with the methylated DNA antibody having the function, to form a bound body between single-stranded DNA having methylated cytosine (in which single-stranded DNA containing the target DNA region and single-stranded DNA other than the target exist) and the methylated DNA antibody having the function (the bound body formed in this stage includes not only a bound body between single-stranded DNA containing the methylated target DNA region and the methylated antibody, but also a bound body between methylated single-stranded DNA other than the target DNA region and the methylated antibody). Upon dropping (introduction) of the obtained bound body into an introduction part, it migrates in a development part, and single-stranded DNA containing the methylated target DNA region binds to the biotinylated specific oligonucleotide that has been already trapped, to form a complex of single-stranded DNA containing the methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having the function (in this stage, the bound body between

methylated single-stranded DNA other than in the target DNA region and a methylated antibody fails to form a complex). By quantifying or detecting the methylated DNA antibody contained in the obtained complex according to its function, methylated DNA in the target DNA region can be quantified or detected.

[0192] Also a plurality of detection sites may be provided on a single chromatostrip (the specific oligonucleotides capable of trapping different target DNA regions are immobilized to a support), and each target DNA region may be sequentially quantified or detected, and by enabling one detection site to trap a plurality of target DNA regions, or by immobilizing a number of the specific oligonucleotides capable of trapping a plurality of target DNA regions on one detection site, it is possible to dramatically improve the detection sensitivity. Also, using a number of the specific oligonucleotides having the function capable of trapping a plurality of target DNA regions so as to allow formation of a complex with a plurality of target DNA regions will also improve the detection sensitivity dramatically. Further, designing a number of the specific oligonucleotides in a single target region, and using these on the side of a support or on the side of detection will also improve the detection sensitivity dramatically.

[0193] The restriction enzyme, the specific oligonucleotide, or the methylated DNA antibody which may be used in the present invention as described above is useful as a reagent in a detection kit. The present invention also provides a detection kit containing such a restriction enzyme, the specific oligonucleotide, or the methylated DNA antibody and so on as a reagent, and a detection chip including a support on which the specific oligonucleotide, or the methylated DNA antibody and so on is immobilized, and the scope of the present invention implies use in the form of a detection kit or a detection chip as described above utilizing a substantial principle of the method.

Examples

[0194] In the following, the present invention will be explained in detail by way of examples, which are not intended to limit the present invention.

Example 1

[0195] A colon-adenocarcinoma cell strain Capan-2 (ATCC NO. HTB-80) derived from a mammal and purchased from ATCC was cultured to be confluent in a culture medium in which equivalent amounts of McCoy's5a (Gibco, Cat. No. 16600-082) and FBS (ATCC, CatNo. 30-2020) were mixed, to obtain about 1×10^7 of cells. The obtained cells were added with a SEDTA buffer [10 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 100 mM NaCl] in a volume of 10 times, and homogenized.

[0196] The obtained mixture was added with proteinase K (Sigma) in a concentration of 500 $\mu\text{g}/\text{mL}$ and sodium dodecyl sulfate in a concentration of 1% (w/v), and shaken at 55° C. for about 16 hours, and then subjected to a phenol/chloroform extraction treatment using phenol saturated with 1 M Tris-HCl, pH 8.0. The aqueous layer was collected, and added with NaCl in a concentration of 0.5 N, and the precipitate (genomic DNA) generated by an ethanol precipitation treatment was collected. The collected precipitate was dissolved in a TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0), and added with RNase A (Sigma) in a concentration of 40 $\mu\text{g}/\text{ml}$, and incu-

bated at 37° C. for 1 hour, and then subjected to a phenol/chloroform extraction treatment. The aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and the precipitate (genomic DNA) generated by an ethanol precipitation treatment was collected. The collected precipitate was rinsed with 70% ethanol, to obtain Capan-2 genomic DNA.

[0197] Each of 500 ng/20 μ L solutions in TE buffer of Genomic DNA derived from human blood purchased from Clontech, and the above-described Capan-2 genomic DNA was prepared in duplicate.

[0198] Each 20 μ L of the prepared genomic DNA solution, 10 U of restriction enzyme XspI, and 5 μ L of 10 \times buffer optimum for XspI (200 mM Tris-HCl pH 8.5, 100 mM MgCl₂, 10 mM Dithiothreitol, 1000 mM KCl) were mixed, and added with sterilized ultrapure water to make the liquid volume 50 μ L, and the liquid was incubated at 37° C. for 1 hour, to prepare a genome solution.

[0199] As a specific oligonucleotide used for obtaining a target DNA region of either of SEQ ID NOs: 1 to 12, 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NOs: 13 to 24, and binding to the DNA region by complementation was synthesized, and each 0.1 pmol/ μ L solution in TE buffer was prepared in the following manner.

[0200] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 13 for obtaining a target region of SEQ ID NO: 1 was named a specific oligonucleotide solution 1.

[0201] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 13 for obtaining a target region of SEQ ID NO: 1 was named a specific oligonucleotide solution 1.

[0202] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 14 for obtaining a target region of SEQ ID NO: 2 was named a specific oligonucleotide solution 2.

[0203] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 15 for obtaining a target region of SEQ ID NO: 3 was named a specific oligonucleotide solution 3.

[0204] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 16 for obtaining a target region of SEQ ID NO: 4 was named a specific oligonucleotide solution 4.

[0205] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 17 for obtaining a target region of SEQ ID NO: 5 was named a specific oligonucleotide solution 5.

[0206] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 18 for obtaining a target region of SEQ ID NO: 6 was named a specific oligonucleotide solution 6.

[0207] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 19 for obtaining a target region of SEQ ID NO: 7 was named a specific oligonucleotide solution 7.

[0208] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 20 for obtaining a target region of SEQ ID NO: 8 was named a specific oligonucleotide solution 8.

[0209] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 21 for obtaining a target region of SEQ ID NO: 9 was named a specific oligonucleotide solution 9.

[0210] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 22 for obtaining a target region of SEQ ID NO: 10 was named a specific oligonucleotide solution 10.

[0211] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 23 for obtaining a target region of SEQ ID NO: 11 was named a specific oligonucleotide solution 11.

[0212] A solution of 5'-end biotinylated oligonucleotide having a nucleotide sequence of SEQ ID NO: 24 for obtaining a target region of SEQ ID NO: 12 was named a specific oligonucleotide solution 12.

[0213] Equivalent amounts of the specific oligonucleotide solutions 1 to 12 were mixed, to prepare a specific oligonucleotide solution 13.

[0214] As a counter oligonucleotide designed with respect to the nucleotide sequence in the target region of either of SEQ ID NOs: 1 to 12, an oligonucleotide of either of SEQ ID NOs: 25 to 118 was synthesized, and respective 10 pmol/ μ L solutions in TE buffer were prepared. Equivalent amounts of the counter oligonucleotide solutions targeting the same DNA region were mixed, to prepare respective counter oligonucleotide mixed solutions shown below.

[0215] A mixed solution of oligonucleotides of SEQ ID NOs: 25 to 42 was named a counter oligonucleotide mixed solution 1.

[0216] A mixed solution of oligonucleotides of SEQ ID NOs: 43 to 60 was named a counter oligonucleotide mixed solution 2.

[0217] A mixed solution of oligonucleotides of SEQ ID NOs: 61 to 66 was named a counter oligonucleotide mixed solution 3.

[0218] A mixed solution of oligonucleotides of SEQ ID NOs: 67 to 70 was named a counter oligonucleotide mixed solution 4.

[0219] A mixed solution of oligonucleotides of SEQ ID NOs: 71 to 76 was named a counter oligonucleotide mixed solution 5.

[0220] A mixed solution of oligonucleotides of SEQ ID NOs: 77 to 82 was named a counter oligonucleotide mixed solution 6.

[0221] A mixed solution of oligonucleotides of SEQ ID NOs: 83 to 88 was named a counter oligonucleotide mixed solution 7.

[0222] A mixed solution of oligonucleotides of SEQ ID NOs: 89 to 94 was named a counter oligonucleotide mixed solution 8.

[0223] A mixed solution of oligonucleotides of SEQ ID NOs: 95 to 100 was named a counter oligonucleotide mixed solution 9.

[0224] A mixed solution of oligonucleotides of SEQ ID NOs: 101 to 106 was named a counter oligonucleotide mixed solution 10.

[0225] A mixed solution of oligonucleotides of SEQ ID NOs: 107 to 112 was named a counter oligonucleotide mixed solution 11.

[0226] A mixed solution of oligonucleotides of SEQ ID NOs: 113 to 118 was named a counter oligonucleotide mixed solution 12.

[0227] Equivalent amounts of the above counter oligonucleotide mixed solutions 1 to 12 were mixed, to prepare a counter oligonucleotide mixed solution 13.

[0228] Equivalent amounts of a specific oligonucleotide solution and a counter oligonucleotide mixed solution were mixed, to prepare the following Solution A, Solution B and Solution C.

[0229] Solution A: specific oligonucleotide solution 1 and counter oligonucleotide mixed solution 1

[0230] Solution B: specific oligonucleotide solution 2 and counter oligonucleotide mixed solution 2

[0231] Solution C: specific oligonucleotide solution 13 and counter oligonucleotide mixed solution 13

[0232] In a PCR tube, 30 μ L of the genome solution prepared as described above, 30 μ L of either one of the Solutions A to C, 15 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 60 μ L of a 10 mM MgCl₂ solution, and 15 μ L of a 1 mg/mL BSA solution were added, to make the liquid volume 150 μ L, and mixed. Then, the PCR tube was heated at 95° C. for 10 minutes, rapidly cooled to 70° C., and retained for 10 minutes at that temperature. Then the reaction was cooled to 50° C. and retained for 10 minutes, and further retained at 37° C. for 10 minutes, and then the reaction was returned to room temperature, to promote formation of a bound body between the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

[0233] All the obtained mixtures were transferred to wells coated with streptavidin, and left still for about 30 minutes at room temperature, to immobilize the bound bodies between the 5'-end biotin-labeled oligonucleotides and the DNA fragments to wells. Thereafter, the solution was removed by pipetting, and each well was washed with 200 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4)] three times.

[0234] Each well was added with 100 μ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5 μ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4) solution], and left still for 1 hour at room temperature. Solutions in wells were removed by pipetting, and each well was washed with 200 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4)] three times.

[0235] Each well was added with 100 μ L of an Eu-N1-labeled mouse IgG antibody [available from PerkinElmer, 0.05 μ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4) solution], and left still at room temperature for 1 hour, and then solutions in the wells were removed by pipetting, and each

well was washed with 200 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄·7H₂O, 154 mM NaCl pH 7.4)] three times.

[0236] Each well was added with 150 μ L of Enhancement Solution (available from PerkinElmer), stirred for 5 minutes at room temperature, and left still for 15 minutes at room temperature, and then fluorescence was measured at excitation 340 nm/fluorescence 612 nm.

[0237] The result is shown in FIG. 1. Methylation frequency or an index value correlated therewith was high in the Solution C that simultaneously detects a plurality of target regions to be detected, compared to the Solution A and Solution B in which the target region to be detected is one kind. The index value correlated with methylation frequency of the target region to be detected was higher in genomic DNA extracted from Capan-2 cancer cell strain, than in human genomic DNA derived from a noncancerous cell.

[0238] In the present experiment, by simultaneously measuring methylation frequencies or index values correlated therewith of a plurality of target DNA regions, it is possible to measure methylation frequency or an index value correlated therewith more effectively than measuring methylation frequency or an index value correlated therewith of one target DNA region. Also, the higher methylation frequency or the index value correlated therewith in genomic DNA derived from Capan-2 cell strain which is a pancreatic cancer cell than in genomic DNA derived from a noncancerous tissue reveals that measurement of methylation frequency or an index value correlated therewith by mixing the target DNA regions used in the present examination will be a diagnostic index of cancer. Also it was confirmed that mixing of a specific oligonucleotide and a counter oligonucleotide, and the specific oligonucleotides utilized in the present examination is useful for cancer diagnosis.

INDUSTRIAL APPLICABILITY

[0239] Based on the present invention, it becomes possible to provide a method of quantifying or detecting methylated DNA in a target DNA region in a genomic DNA contained in a biological specimen in a simple and convenient manner, and so on.

[0240] Free Text in Sequence Listing

[0241] SEQ ID NOs:13 to 24

[0242] Designed biotinized oligonucleotide for fixation

[0243] SEQ ID NOs:25 to 118

[0244] Designed oligonucleotide

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 134

<210> SEQ ID NO 1

<211> LENGTH: 1138

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

taggaaagaa tagttttgct ttttcttatg attaaaagaa gaagccatac tttccctatg 60

acaccaaaaca ccccgattca atttggcagt taggaaggtt gtatcgcgga ggaaggaaac 120

-continued

```

ggggcggggg cgatttctt ttaacagag tgaacgcact caaacacgcc ttgctggca 180
ggcgggggag cgcggtctgg agcagggagg ccggagggcg gtgtgggggg caggtgggga 240
ggagcccagt cctcctctct tgccaacgct ggctctggcg agggctgctt ccggctggtg 300
ccccggggg agaccacaac tggggcgact tcaggggtgc cacattcgtt aagtgtcgg 360
agttaatagc acctcctcgg agcactcgtt cacggcgtcc ccttgctcgg aaagataccg 420
cgtccctcc agaggatttg agggacaggg tcggaggggg ctcttccgcc agcaccggag 480
gaagaaagag gaggggctgg ctggtcacca gaggggtggg cggaccgcgt gcgctcggcg 540
gctcgggaga gggggagagc aggcagcggg cggcggggag cagcatggag ccggcggcgg 600
ggagcagcat ggagccttgg gctgactggc tggccacggc cgcggcccgg ggtcgggtag 660
aggagggtcg ggcgtcgtg gaggcggggg cgtgcccga cgcaccgaat agttacggtc 720
ggagggcgat ccaggtgggt agaggtctg cagcgggagc aggggatggc gggcgactct 780
ggaggacgaa gtttgcaggg gaattggaat caggtagcgc ttcgattctc cggaaaaagg 840
ggaggcttcc tggggagttt tcagaagggg ttgtaatca cagacctctt cctggcgacg 900
ccctgggggc ttgggaagcc aaggaagagg aatgaggagc cacgcgcgta cagatctctc 960
gaatgctgag aagatctgaa ggggggaaca tatttgtatt agatggaagt atgctcttta 1020
tcagatacaa aatttacgaa cgtttgggat aaaaaggag tcttaaagaa atgtaagatg 1080
tgctgggact acttagcctc caattcacag atacctggat ggagcttata tttcttac 1138

```

```

<210> SEQ ID NO 2
<211> LENGTH: 875
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 2

```

```

tagccagata ttccctcggg gggccgagag tcttccctat cagaccccgg gatagggatg 60
aggcccacag tcaccacca gactccttgt atagcccgt taagtgcacc ccggcctgga 120
gggggtggtt ctgggtagaa gcacgtccgg gccgcgccgg atgcctcctg gaaggcgcct 180
ggaccacgc caggtttccc agtttaattc ctcatgactt agcgtcccag ccgcgcacc 240
gaccagcgc ccagttcccc acagacgcgc gcgggcccg gagcctcgcg gacgtgacgc 300
cgcgggcgga agtgacgttt tcccgcggtt ggacgcggcg ctcaagtgcc gggcggggga 360
ggcgcgtcc ggtttttctc aggggacgtt gaaattatth ttgtaacggg agtcgggaga 420
ggacggggcg tccccgacg tgcgcgcgcg tcgtcctccc cggcgctcct ccacagctcg 480
ctggtccccg ccgcggaag gcgtcatgcc gcccaaaacc ccccgaaaaa cggccgccac 540
cgcgcgcgct gccgcgcggg aacccccggc acgcgcgcgc ccgccccctc ctgaggagga 600
cccagagcag gacagcggcc cggaggacct gcctctcgtc aggtgagcga gcagagccgc 660
cgtcgcctca cgcgggaagg gcgccccggg tgtgcgtagg gggggcgcca agcgggctcg 720
cgggggatcc gtctcgcga ggggcgggt cccggcggga ggaggcgcgc tcctgcccc 780
cgcacaggcg gacgctctgc agaattgtga caggattctg ggttcttggg cgaggggtct 840
cgcttcaac ttgacagggt tcggggcggg ggggc 875

```

```

<210> SEQ ID NO 3
<211> LENGTH: 596
<212> TYPE: DNA

```

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

```

taggggaacc aaactctgtt tccaggggag tggagagaga aactgggtcc ccctcccgta    60
gctcctggga cacagetgag ccagccacag gatctgggga caaccggggc ggatccccc    120
tttcgggagg cggtggtatc agttcagagt ccgcattttt attcatcggg gaagcgtggg    180
gagaaggatg ggtcggagct gggctcctgt ctgaaggaca gcagtccgga gctaacggtt    240
gagtctccaa agtcttcata ctgcagagga agcacagcgg agattagcct cagccaggat    300
ggcttcgaag ttctcagga tccgacgag agctaagaa acccacctgt gcttccctcc    360
tctctcggga gtaggcagaa gactcccggg aggagaggcg aacagcggac gccaaattctt    420
ttgaaagcac tgtgttctt agcaccgcgg gtcgctacgg gctctttgct gtcgcgggat    480
ttcgggtccac cttccgattg gggcgcgcga tcccggatca gatttcgagg ggcacccacg    540
gaacccgcgg agccgggacg tgaaggtta gaaggtttcc cgttcccatc aagccc    596

```

<210> SEQ ID NO 4

<211> LENGTH: 831

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

```

tagggctcct cgtggctgct gggagttgta gtctgaacgc ttctatcttg gcgagaagcg    60
cctacgctcc ccctaccgag tcccgcggta attcttaaag cacctgcacc gcccccccgc    120
cgctgcaga gggcgcagca ggtcttgca cttcttgca tctcattctc caggcttcag    180
acctgtctcc ctcatcmeta aaatatttat tatcgagctc ttacttgcta cccagcactg    240
atataggcac tcaggaatac aacaatgaat aagatagtag aaaaattcta taccctcata    300
aggcttacgt ttccatgtac tgaagcaat gaacaaata atcttatcag agtgataagg    360
gttgtaagg agattaata agatggtgtg atataaagta tctgggagaa aacgttaggg    420
tgtgatatta cggaaagcct tccmetaaaa tgacatttta actgatgaga agaaaggatc    480
cagctgagag caaacgmeta agctttcttc cttccacctc tcatattga cacaatgcag    540
gattcctcca aaatgatttc caccaattct gccctcacag ctctggettg cagaattttc    600
caccmetaaa tgtagtatac tacggcacca ggtcggcgag aatcctgact ctgcacctc    660
ctccmetaact ccatctctt tgcttctctc ggcaggcgga ttacttgccc ttacttgta    720
tggcgactgt ccagctttgt gccaggagcc tcgcaggggt tgatgggatt ggggttttcc    780
cctcccatgt gctcaagact ggcgmetaaaa gttttgagct tctmetaaagt c    831

```

<210> SEQ ID NO 5

<211> LENGTH: 623

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

```

tagggggcga gctgctgga gttgcgttcc aggcgtcccg cccctgggccc gtcaccgcgg    60
ggcggccgct ctgagggtgg gaagatggtg gtgggggtgg gggcgcacac agggcgggaa    120
agtggcggtg ggcgggaggg agaggaacgc gggcctgag ccgcccgcgc gcgcgctcc    180
ctacgggcgc ctccggcagc ccttcccgcg tgcgcagggc tcagagccgt tccgagatct    240

```

-continued

```

tggaggtccg ggtgggagtg ggggtgggtt ggggtgggtt gtgaaggtgg ggggcgggcg 300
cgctcagggg aggcgggtgc gcgcctgcgg gccggagatg gccagggggc ggtgcgtggg 360
tcccagtctg cagttaaggg ggcaggagtg gcgctgctca cctctggtgc caaagggcgg 420
cgcagcggct gccagctcgc gccctggagg cggcgagaac atggtgcgca ggttcttgg 480
gaccctccgg attcggcgcg cgtcgggcc gccgcgagt agggttttcg tggttcacat 540
cccgcggctc acgggggagt gggcagcgc aggggcgccc gccctgtgg ccctcgtgct 600
gatgctactg aggagccagc gtc 623

```

```

<210> SEQ ID NO 6
<211> LENGTH: 675
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 6

```

```

tagtcccga tctctggca cacaccacc cactcaggcc ggggtccag cccgcgaggt 60
ttaggacgga tccaggcaga ccgaggtcgc cgggtcgggg caccgggtca gcgcgcccgc 120
ctgaaggcgg cgtcctgggc tcgacttccc gcgcgaggag agccggcgag cccgcgtccg 180
agttcctgga cgagagccga gcctcgetta gaccgcgctc aggaccgggc tctcctcagc 240
tctcggctg cccctgtgtc ctcgactcac cctcctttc tgccgctcct tcttttctt 300
gccctgctt tactgttccc aaacaggacc gcttttctg tctccagct gaaaaggagg 360
aaggagaga gtccagaaag gatcggatg gtggaagaaa aggggaggag gggacatgga 420
gggggagacc ggagagagaa cgtacgcca ggagtcaggc ggcgggatca aggggagtcg 480
gggtgtctg gcgcggggca gacggtggag gcggcagcgg ccaacggctc ccaagacaac 540
cattctacgc gaggacgcgg gcacaggagg ggagcggcca gcagggagg ggagcgcggg 600
ggaagaggaa agaggaagaa gcgctcagat gctccgcggc tgtcgtgaag gttaaaaccg 660
aaaataaaaa tgggc 675

```

```

<210> SEQ ID NO 7
<211> LENGTH: 185
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 7

```

```

taggaaggag agagtgcgccc ggagcagcgt gggaaagaag ggaagagtgt cgtaagttt 60
acggccaacg gtgattatc cgggcccgtg ccgctctggg ggctgcgga tgcgcgagga 120
gaacaagggc atgccagctg ggggcggcag cgatgagggt ctggccagcg ccgcgccgcg 180
gggac 185

```

```

<210> SEQ ID NO 8
<211> LENGTH: 450
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 8

```

```

tagaaccag tcagagggca gcttagcaat gtgtcacagg tggggcggcc gcgttccggg 60
cggacgcact ggctccccg ccggcgtggg tgtggggcga gtgggtgtgt gcggggtgtg 120
cgcggtagag cgcgccagcg agcccggagc gcggagctgg gaggagcagc gagcgcggcg 180

```

-continued

```

cagaaccgagc agcgccggcc tggcagggca gctcggaggt gggtagggcg cgccggcage 240
ccgcttgacg ggtccccatt ggccgcctgc cgcccccct cggcccaaaa ggcggcaagg 300
agccgagagg ctgcttcgga gtgtgaggag gacagccgga ccgagccaac gccggggact 360
ttgttccctc cgcgaggggg actcggcaac tcgcagcggc agggctctggg gccggcgct 420
gggagggatc tgcgcccccc actcactccc 450

```

```

<210> SEQ ID NO 9
<211> LENGTH: 1315
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 9

```

```

tagtctccgg cgctggcgcc tatggctggc ctccgacagc gctccggagg gaccggggga 60
gctcccaggc gcccggtgta gtagccaggc gcggctcccc ggtcccccg acccccggcg 120
ccagcttttg ctttcccagc cagggcggcg tggggtttgt ccgggcagtg cctcgagcaa 180
ctgggaaggc caagcgggag ggaacttgg cttcggggag aagtgcgac gcagccggga 240
ggcttccccg gccccggcg ccgggtgaga acaggtggcg ccggcccagc caggcgcttt 300
gtgtcggggc gcgaggatct ggagcgaact gctgcgcctc ggtgggcgcg tcccttccct 360
cccttgctcc cccggggcgc cgcacgcggg gtcggccggg taacggagag ggagtgcga 420
ggaatgtggc tctggggact gcctcgctcg ggaaggggg gagggtagcc acggtgtag 480
gagaggcgcg ggagccgaga ggtggcgcg ggggtgccacc gttgccgag gctggagaga 540
gattgctccc agtgaggcgc gtaccgtctg ggcgagggct tcattcttcc gcggcgctcc 600
tggaggtggg aaagctgggt gggcatgtgt gcagagaaag gggagggcgg gagccagtc 660
acttccggag ccggttctga tcccacaga ccgccagcg tttggggacg ccgacctcgg 720
ggtgccgtgg tccccggccc caccgcgcgc cggggctgag gggtcggggg cgtccctggc 780
cgcccagctt taacaaaggg tgctcctctc cccccgcga ggaggggag ctccggagac 840
ccggtcttca gcgagcgggg tcttagcgcc ggggaggtct acttctttt ggggttgcca 900
ttttactatt attattgctt ttttttttcc ttcaaaagga ctggagactg atgcatgagg 960
gggctacgga ggcgcaggag cgggtggtgat ggtctgggaa gcggagctga agtgccctgg 1020
gctttggtga ggcgtgacag tttatcatga ccgtgttcag gcaggaaaac gtggatgatt 1080
actacgacac cggcgaggaa cttggcaggt aaaggggta ccagaagcgt accctcctgg 1140
attgtgaaa tgacataacga tggggccatt ggggtgtaaa caaatgcagt ttgaatcagg 1200
cgtctccctc gccctttctg gagatgcgca aatcatagag aaaagagtta ctaaccagc 1260
ggtaaacgca ctgatccaag ggcctggggg tggaggagag gcagcagttc agggc 1315

```

```

<210> SEQ ID NO 10
<211> LENGTH: 294
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 10

```

```

tagcacagta aagctggcct ccagaaacac gggatatctc gcgtgggtgct ttgcggtcgc 60
cgtcggttg ggcgtccggg gtgggggtgt aggaggggac gaaggaggga aggaagggca 120
aggcgggggg ggcctctgca gacgcgccc agccccgct tcgggccccca cagtcctgca 180

```

-continued

```
accaggttt ccattgcgc gctctctca gtccttccc gccgccagt ctggatcctg 240
```

```
ggggaggcgc tgaagtcggg gcccgccctg tggccccgc cggcccgcc ttgc 294
```

```
<210> SEQ ID NO 11
```

```
<211> LENGTH: 592
```

```
<212> TYPE: DNA
```

```
<213> ORGANISM: Homo sapiens
```

```
<400> SEQUENCE: 11
```

```
tagttagaaa aagccaaaga ttgtgcgatt tatgccccaa accccttgt aaggggattc 60
```

```
tcacctcaac ttgtcttctg tggtcagtgt ttccccccc tgaatcaggg ttactgtcac 120
```

```
tatggcttcc aattggccc gcgtaggcgc atgctctgcg cgtattggcc tccgctcctg 180
```

```
tccccagaca agcggccatc ttgggtccc cccctaccgt ggggtcttct gggaaattgca 240
```

```
gtccccctc tgctctgtcc ggtcacagga ctttttgccc tctgttccc ggtccctcag 300
```

```
gcgccacccc agtgggcaca ctcccaggcg gcgctccgccc cccgcgctcc ctccctctgc 360
```

```
ctttcattcc cagctgtcaa catcctggaa ggtaggggccc gggaggcaag cccaagtgga 420
```

```
atactgttcc tggggcgcgc gctctgggtt ccacgcgcgt caggtcatca ccccggagcc 480
```

```
cagtggggcc ggcgcgctc acggggcggt gggcttctgt cccgagtact cttccgcccc 540
```

```
acgaggtctc caggtgggg actcgggccc cccaattccc aagcaccgac cc 592
```

```
<210> SEQ ID NO 12
```

```
<211> LENGTH: 729
```

```
<212> TYPE: DNA
```

```
<213> ORGANISM: Homo sapiens
```

```
<400> SEQUENCE: 12
```

```
taggcaggct gtgcggttgg gcggggccct gtccccact gcggagtgcg ggtcggaag 60
```

```
cggagagaga agcagctgtg taatccgctg gatgcggacc agggcgctcc ccattcccgt 120
```

```
cgggagccc cagattggct ggggtgtggc gcacgtgacc gacatgtggc tgtattggtg 180
```

```
cagcccgcca ggggtgctact ggagacagaa tggaggtgct gccggactcg gaaatggggt 240
```

```
agggtgctgga gccaccatgg ccaggcttgc tgcgggggga ggggggaagg tggttttccc 300
```

```
tcgcaactgc ttaaacgat ggcttttctc tggcacaggg tccactgcag catgccaaac 360
```

```
gaggaggcag gggcgctgct ccccccccc ccaactgcagc actggagatg gatttcctgt 420
```

```
acttcgcatc caggtttttt gacagaagag gaagaagggg gaggggtaga agtgtaagg 480
```

```
ggagtctgct gagaaaagct gtttttgaag ccagaagggg tttttgttt tataatgcca 540
```

```
tttgacagag tggaaataca gtatctaagg aaacgggtag aggacaacaa agaatggagc 600
```

```
atattcatgg cgaggagcaa aagctctacc ccattgaaag gcttttttcc ctccctggcg 660
```

```
acaaggacac atgcattggt ggccaaaaga gagaggagac aaaaccgctg cagatggctg 720
```

```
atgtgaatc 729
```

```
<210> SEQ ID NO 13
```

```
<211> LENGTH: 22
```

```
<212> TYPE: DNA
```

```
<213> ORGANISM: Artificial Sequence
```

```
<220> FEATURE:
```

```
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation
```

```
<400> SEQUENCE: 13
```

-continued

atagggaaag tatggettct tc 22

<210> SEQ ID NO 14
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

<400> SEQUENCE: 14

aagtcattgag gaattaaact gg 22

<210> SEQ ID NO 15
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

<400> SEQUENCE: 15

gtgcttcctc tgcagtatga ag 22

<210> SEQ ID NO 16
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

<400> SEQUENCE: 16

acccttatca ctctgataag at 22

<210> SEQ ID NO 17
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

<400> SEQUENCE: 17

tggtcctca gtagcatcag ca 22

<210> SEQ ID NO 18
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

<400> SEQUENCE: 18

cctcctttcc agctgggaga ca 22

<210> SEQ ID NO 19
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for
fixation

-continued

<400> SEQUENCE: 19
cactgggcat gcccttggtc tc 22

<210> SEQ ID NO 20
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation

<400> SEQUENCE: 20
acctgtgaca cattgctaag ct 22

<210> SEQ ID NO 21
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation

<400> SEQUENCE: 21
tgggagcaat ctctctccag cc 22

<210> SEQ ID NO 22
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation

<400> SEQUENCE: 22
aacctgggtg cagggactgt gg 22

<210> SEQ ID NO 23
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation

<400> SEQUENCE: 23
aactgacca cagaagacaa gt 22

<210> SEQ ID NO 24
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed biotinated oligonucleotide for fixation

<400> SEQUENCE: 24
cttagatact gttattccac tc 22

<210> SEQ ID NO 25
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 25

ccaacgctgg ctctggcgag ggctgcttcc 30

<210> SEQ ID NO 26

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 26

ggctggtgcc cccgggggag acccaacctg 30

<210> SEQ ID NO 27

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 27

gggcgaactc aggggtgcc cattcgctaa 30

<210> SEQ ID NO 28

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 28

gtgctcggag ttaatagcac ctctccgag 30

<210> SEQ ID NO 29

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 29

cactcgctca cggcgtcccc ttgcctggaa 30

<210> SEQ ID NO 30

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 30

agataccgcg gtcctccag aggatttgag 30

<210> SEQ ID NO 31

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 31

-continued

ggacagggtc ggagggggct cttccgccag 30

<210> SEQ ID NO 32
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 32

caccggagga agaaagagga ggggctggct 30

<210> SEQ ID NO 33
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 33

ggtcaccaga gggtagggcg gaccgcgtgc 30

<210> SEQ ID NO 34
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 34

gctcggcggc tgcggagagg gggagagcag 30

<210> SEQ ID NO 35
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 35

gcagcgggcg gcggggagca gcatggagcc 30

<210> SEQ ID NO 36
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 36

ggcggcgggg agcagcatgg agccttcggc 30

<210> SEQ ID NO 37
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 37

tgactggctg gccacggcgg cggcccgggg 30

<210> SEQ ID NO 38

-continued

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 38

tccggtagag gaggtgcggg cgctgctgga 30

<210> SEQ ID NO 39
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 39

ggcgggggcg ctgcccaacg caccgaatag 30

<210> SEQ ID NO 40
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 40

ttacggtcgg aggccgatcc aggtgggtag 30

<210> SEQ ID NO 41
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 41

agggtctgca gcgggagcag gggatggcgg 30

<210> SEQ ID NO 42
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 42

gcgactctgg aggacgaagt ttgcagggga 30

<210> SEQ ID NO 43
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 43

cacagacgcc ggcgggcccg ggagcctcgc 30

<210> SEQ ID NO 44
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 44

ggacgtgacg cgcggggcgg aagtgacgtt 30

<210> SEQ ID NO 45

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 45

ttcccgggt tggacgcggc gctcagttgc 30

<210> SEQ ID NO 46

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 46

cgggcggggg agggcgcgtc cggtttttct 30

<210> SEQ ID NO 47

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 47

caggggacgt tgaattatt tttgtaacgg 30

<210> SEQ ID NO 48

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 48

gagtcgggag aggacggggc gtgccccgac 30

<210> SEQ ID NO 49

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 49

gtgcgcgcgc gtcgtctccc ccggcgctcc 30

<210> SEQ ID NO 50

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 50

-continued

tccacagctc gctggctccc gcccggaaa 30

<210> SEQ ID NO 51
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 51

ggcgtcatgc cgccaaaac cccccgaaa 30

<210> SEQ ID NO 52
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 52

acggccgcca ccgcccgcg tgcccgcg 30

<210> SEQ ID NO 53
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 53

gaacccccgg caccgccc gccgcccct cct 33

<210> SEQ ID NO 54
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 54

ggacagcggc ccggaggacc tgccctcgt 30

<210> SEQ ID NO 55
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 55

caggtgagcg agcagagccg ccgtgcctc 30

<210> SEQ ID NO 56
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 56

acgcgggaag ggcgccccg gtgtgcgtag 30

<210> SEQ ID NO 57

-continued

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 57

ggcgggcgcc aaggcggtc ggcgggatc 30

<210> SEQ ID NO 58
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 58

cgctctcgcc agggccggg tcccggcggg 30

<210> SEQ ID NO 59
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 59

aggagcgcc ctccctgccc cccgccacg 30

<210> SEQ ID NO 60
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 60

cggagcgtct gcagaatggt gacaggattc 30

<210> SEQ ID NO 61
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 61

ctcccgggag gagaggcga cagcggacgc caat 34

<210> SEQ ID NO 62
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 62

ttagcaccgc gggtegctac gggcctcttg 30

<210> SEQ ID NO 63
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 63

ctgtcgcggg atttcgggtcc accttccgat 30

<210> SEQ ID NO 64
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 64

tgggcccgcg catcccggat cagatttcgc 30

<210> SEQ ID NO 65
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 65

gggcgaccca cggaaccgc ggagccggga 30

<210> SEQ ID NO 66
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 66

cgtgaaaggt tagaaggttt cccgttccca 30

<210> SEQ ID NO 67
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 67

ctgaacgctt ctatcttggc gagaagcgcc 30

<210> SEQ ID NO 68
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 68

tacgctcccc ctaccgagtc ccgcgtaat 30

<210> SEQ ID NO 69
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 69

-continued

tcttaaagca cctgcaccgc cccccgcg 30

<210> SEQ ID NO 70
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 70

cctgcagagg gcgcagcagg tcttgacct 30

<210> SEQ ID NO 71
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 71

caaagggcgg cgcagcggct gccgagctcg 30

<210> SEQ ID NO 72
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 72

gccctggagg cggcgagaac atggtgcgca 30

<210> SEQ ID NO 73
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 73

ggttcttggg gaccctccgg attcgccg 30

<210> SEQ ID NO 74
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 74

cgtgcccgc gccgcgagtg agggtttctg 30

<210> SEQ ID NO 75
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 75

tggttcacat cccgcggetc acgggggagt 30

<210> SEQ ID NO 76

-continued

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 76

gggcagcgcc agggcgccc gccgctgtgg 30

<210> SEQ ID NO 77
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 77

agggggagac cggagagaga acgtacgccg 30

<210> SEQ ID NO 78
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 78

aggagtcagg cggcgggatc aaggggagtc 30

<210> SEQ ID NO 79
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 79

ggggtgtctg ggcgcggggc agagcgtgga 30

<210> SEQ ID NO 80
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 80

ggcggcagcg gccaacggtc gccaaagaaa 30

<210> SEQ ID NO 81
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 81

ccattctacg cgaggacgcg gcgacaggag 30

<210> SEQ ID NO 82
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 82

gggagcggcc agcaggggag gggagcgcgg gggaa 35

<210> SEQ ID NO 83
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 83

taggaaggag agagtgcgcc ggagcagcgt 30

<210> SEQ ID NO 84
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 84

gggaaagaag ggaagagtgt cgттаagttt 30

<210> SEQ ID NO 85
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 85

acggccaacg gtggattatc cgggccgctg 30

<210> SEQ ID NO 86
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 86

cgcgtctggg ggctgcggaa tgcgcgagga 30

<210> SEQ ID NO 87
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 87

gaacaagggc atgccagtg gggcggcag 30

<210> SEQ ID NO 88
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 88

-continued

cgatgagggt ctggccagcg ccgcggcgcg gggac 35

<210> SEQ ID NO 89
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 89

ccccattggc cgectgcccg ccgcccctccg ccc 33

<210> SEQ ID NO 90
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 90

aaaaggcggc aaggagccga gaggtgctt 30

<210> SEQ ID NO 91
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 91

cgagtgatga ggaggacagc cggaccgagc 30

<210> SEQ ID NO 92
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 92

caacgcggg gactttgttc cctccgcca 30

<210> SEQ ID NO 93
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 93

ggggactcgg caactcgcag cggcagggtc 30

<210> SEQ ID NO 94
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 94

tggggcggc gcctgggagg gatctgcgcc cccc 34

<210> SEQ ID NO 95

-continued

<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 95

tagtctccgg cgctggcgcc tatggtcggc ctccg 35

<210> SEQ ID NO 96
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 96

acagcgctcc ggagggaccg ggggagctcc 30

<210> SEQ ID NO 97
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 97

caggcgcccc ggtgagtagc caggcgcgcc 30

<210> SEQ ID NO 98
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 98

tccccggtcc ccccgacccc cggcgccagc 30

<210> SEQ ID NO 99
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 99

ttttgctttc ccagccaggg cgcggtgggg 30

<210> SEQ ID NO 100
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 100

tttgccggg cagtgccctcg agcaactggg 30

<210> SEQ ID NO 101
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 101

ctctgcgaga ggcgcccag ccccgcttc gggcc 35

<210> SEQ ID NO 102

<211> LENGTH: 31

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 102

ttgcgggct ctctcagct ccttccgcc g 31

<210> SEQ ID NO 103

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 103

cccagttctgg atctggggg aggcgtgaa gtcg 34

<210> SEQ ID NO 104

<211> LENGTH: 35

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 104

gggcccgcc tgtggcccg cccggcccgc gcttg 35

<210> SEQ ID NO 105

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 105

tccagaaaca cgggtatctc cgcgtgtgc 30

<210> SEQ ID NO 106

<211> LENGTH: 33

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 106

tttgcggtcg ccgctgttg ggcgctcgg ggt 33

<210> SEQ ID NO 107

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 107

-continued

ccaagtggaa tactgtttct ggggcgcggg 30

<210> SEQ ID NO 108
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 108

tctgggtttc cacgcgcgtc aggtcatcac 30

<210> SEQ ID NO 109
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 109

cccggagccc agtggggccg gcgccgtca 30

<210> SEQ ID NO 110
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 110

cggggcggtg ggcttctgtc ccgagtactc 30

<210> SEQ ID NO 111
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 111

ttccgcccc cgaggtctc aggggtggga 30

<210> SEQ ID NO 112
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 112

ctcgggcccc ccaattcccc agcaccgacc 30

<210> SEQ ID NO 113
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 113

gttgggctgg gcctctgtcc ccaactgcga 30

<210> SEQ ID NO 114

-continued

```

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 114

gtgcgggtcg ggaagcggag agagaagcag          30

<210> SEQ ID NO 115
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 115

ctgtgtaatc cgctggatgc ggaccagggc          30

<210> SEQ ID NO 116
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 116

gctccccatt cccgtcggga gcccgccgat          30

<210> SEQ ID NO 117
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 117

tggctgggtg tgggcgcacg tgaccgacat          30

<210> SEQ ID NO 118
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Designed oligonucleotide

<400> SEQUENCE: 118

gtggctgtat tggtgcagcc cggcagggtg          30

<210> SEQ ID NO 119
<211> LENGTH: 2661
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 119

acagacatgt gccaccatgc ccagctaatt tttgtttgt ttgtttgttt gtttatttt          60
ttagtagaga tggggttttg ccatggttggc caggctggtc togaactcct gacctcgaat          120
gataatgatc cgccgcttgg cctccaaagt gctaggatta caggtgtgag ccaactgcgc          180
aggcctgggc actttcttta gtagtttgag gagcaacatt tttgacagtg tccttctgct          240
caagattcaa gatcccagat aaaattaaac catctagaga gatggcttga ttggcctaac          300

```

-continued

ctggatctca tgaccacttc ttgaagtggg taagtctcat aaatgctcag tccttccact	360
atgcaactga gtgggggtggg tgggaagccc ctcaaaggaa aatccggttg ttcttactag	420
aaagaaaagg aaaatggatg tgaggcagtc aaaatcagca gaggtccacc acaccaccaa	480
aatgtggtga ttaaatatgg agagacagag actaacagag gtatgtgaat attgaagtat	540
gtctggacaa tagcccaatg atgagaccaa taaaatgggt accaaaatct ggttttgagt	600
agtagtgta aatcagacca tttagtaacc attttttggt gcaaagtttc tagcactgcc	660
caaaccctga gtggtatatg aataactcgt ccattatgta tctctttcca gtcagcataa	720
tttatcccc acctatattc tttctgacc actcctactt ccttctcttt accaaaatct	780
aaactctaag gctgtttctt cagcaacttc tttgtttaga ttggaagata aattaacag	840
catgcatgt tttactgact ttcagtattt aacagagggt atttaatttt tttttaaatc	900
caaagtcaaa cttctttata agatgaagga gaaaaatgtc ttataaaatg catatgtgaa	960
gatgccttct gagtgccttc tcatgcagac ttgttctagt ctttaatgaa tcttccttgt	1020
agacactgtg gagatgaaag atggttctcc acttctactc aaagtacaaa tcaggccggc	1080
attttgaaaa agagacaggt ttattcatag ctgcagcgtt agctggcttt gttccctgta	1140
caatttcaact tttggttatt aaaatattca ctgtaggaaa taaatttgta acccatttct	1200
catattacct acacacagaa aaacaaaatt tgatatcctg gggtttattt gctgagggcg	1260
cttcccataa aagcgagaga gtgtgcgttg ggaaatgtgt ctggttaact cttttatgga	1320
taaactttag tcacaatcct cccccgccc cctctcacc cccagaccct cccaacctcc	1380
cgacttccc cctctcaagg gctggtgacc taatagcatt tttctctgtg catattttgg	1440
cgtcgcccga tggcctggct gccttcgctt gtctgagttt tttgaaatc ctgcatgttc	1500
gccccagatt aagccagtgt gtctcaggat gtgtgttccg tttgttctt tcccctaac	1560
gctccctgtg caactgtctt ggggggagga gggcagggac gggagagagg gagggcaga	1620
ggcgaggagc tgtccgcctt gcacgtttcc aatcgatta cgtgaacaaa tagctgaggg	1680
gcgccggggc cagaacggct tgtgtaactt tgcaaactg ccagaaaagt taaatctctc	1740
ctccttctt cactccagac actgcccgtt ctccgggact gccgcgccc tcccgttgc	1800
cttccaggac tgagaaagg gaaagggag ggtgccact cagagcagcc gccttgactg	1860
gggaagggc tgaatcccac ccttggcatt gcttgggtga gactgagata cccgtgctcc	1920
gctcgcctcc ttggttgaag atttctcctt ccctcacgtg atttgagccc cgtttttatt	1980
ttctgtgagc caactctcc tcgagcgggg tcaatctggc aaaaggagtg atgcgcttcg	2040
cctggaccgt gctcctgctc gggcctttgc agctctgcgc gctagtgcac tgcgcccctc	2100
ccgcccggc ccaacagcag cccccgccc agccgcccgc ggtccgggc gcctggccc	2160
agcagatcca atgggagaac aacgggcagg tgttcagctt gctgagcctg ggtcacagt	2220
accagcctca gcgcccggg gaccggggc ccgcccctcc tgggtcagcc aacgcctccg	2280
cccagcagcc ccgcaactcc atcctgctga tccgcgacaa ccgcccggc gcggcggaa	2340
cgcgagcggc cggctcatct ggagtcaccg ctggccggcc caggcccacc gcccgctcact	2400
ggtccaagc tggctactcg acatctagag cccggaacc tggcgctcgc cgcgaggaga	2460
accagacagc gccgggagaa gttcctgcgc tcagtaacct gcggcccgc agccgctgg	2520
acggcatggt gggcgacgac ccttacaacc cctacaagta ctctgacgac aaccttatt	2580

-continued

```

acaactacta cgatacttat gaaaggccca gacctggggg caggtaccgg cccggatagc 2640
gcaactggcta cttccagtag g                                     2661

<210> SEQ ID NO 120
<211> LENGTH: 1953
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 120

tataaattcc acgcaggcat tgaattgaat ttgttcttaa ccaaatgcgt tttatctata 60
cctggcagga atctagaagt gaaattacaa gatttatctc attttaattc tattatgaag 120
catttaatac caaatccctc gaaaatgaaa agataattta tcattttacc ttgactgagc 180
aactctcttc acttcacatt catgaatcca taacgcagag aggagactgg atgattaagt 240
gtttgattag agaaaaacaga ttaacctagc aaacataata aatttggtctc ataagcagga 300
tggctttata aatgctcaca atacctctcc tgtataaaat catgaaccac ttctacagt 360
gatgactcca tcgaaatagt tgagaaacat aaagcaaatg catgtttatg gctttctctt 420
tgagacatta aaaggttatt gaaaggcata tctgattcag cttataactc tggatatata 480
ttaaggaaca tgtaagaaaa tattaatgca taaaaaaagc tacaacttct caagtgttct 540
agtttccact ttgtcaataa ttacgttttc aatgtccttc tgtggactgt ttccaaaggt 600
gccaatccag acccaaatgt tcagatcact cagattcacc cttaaccttc ataacacaac 660
ccaatagctt tacgaaaaaa gttgcatatt taggtagttg ttatoccatt atgacaaaaat 720
acataaaaatt agcgagatag tttttagcct tcaaataagt gggaaaaaat ccttttagct 780
gagattccat ttacatcaga ataaaaatct aagttatgac taggttgaag caacgtcctg 840
tgcagcgttc cataaagttc acttagtctt caaggttcc ttacttagct aggttagtat 900
tcctggcctc ttttttagc agtgagaaaa aggatactct cctgccccca gctttatttt 960
taaactcaca gccatctctt ggaggtctct gctggctatt tggcgcgtgg gggcggaggg 1020
gggcccgggg agggggggcg ggcgggtctt ggaggtctgt gctggctatc tggcgtgtgt 1080
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt aggtctctgc tggctatctg gegtgtgtgt 1140
gtgtgtgtgt tgggtgtgtt aagcagtgag gttgttttag ggccagtctt tcctccgcca 1200
ctttgctgac tcaaagacc agaggttttc ttgggtgca ggtaccatga ttcttgggc 1260
cctaagggaa tttttgtag gctagaagag tgggtgtact catgatgggt gtaccgaaac 1320
attctgggc tcaaaaaaac cgattatctt tataaccgcg gcgctagca cagcgcctgg 1380
tgccctaaac gttgctgctg ggaacgtccg agacgcgggt gcggagccgg gggcggaaata 1440
actggttgcg cggcgttttg accgtaggcg ctggagcgcg tgcgttgcgt gcgcgcgcgg 1500
aggcggctgc gtcgggggcg gagaaggtgc agtcccccg cggcggggcg ggcgggcggg 1560
cgaagctggg ctcggggcca agcagaggtc agccggagcg actgtgcccc gcctcctggg 1620
cggagcgggc ggtccccat ggtcagagcc tctgtccggc tcggcagcgc cggacgcgg 1680
agcccagcgc gtcggcccc cggcgtgccc gcgtctcaga gccgcggagg ggcgcgggg 1740
accgtttcag cgtggcggcg ctggtgctgg cgttgccct ggaggacggc cccgagtgat 1800
ggctggcgcc tgctccccg gtgtctcccc ggtacagatg gagtctccc gcggcgcgg 1860
gcccgaaggt cggcagctgc gaggccaaga gagaccccag gacacacaca gctgcctccc 1920

```

-continued

 ggtgcgagaa gaagaccccg gcttgagagt gag 1953

<210> SEQ ID NO 121
 <211> LENGTH: 889
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 121

cggccccatg gctccgtgtc gtgtccaagg gatgggctgg cacctcttgg accaggetta 60
 ccaccagggc ccttctctga agccccagtc tgaccggcct gctgctggga atccccctct 120
 gccccacac taacctctgc tggggctgag ccagggcgcg tcggacagtc agggcgacct 180
 agccaggggc accgttggcc ccgctcctat ggggcagcag ggaccgacgt cagcagggtg 240
 gggcggggcac ccgagtggta tgccccgcc tgccccgct gcccgccctg gtggcctct 300
 gggggcgaca agtctctgaga gaaccagacg gaagcgcgct gggactgaca cgtggacttg 360
 ggcggtgctg cccgggtggg tcagcctggg ctgggaggca gccccgggac acagctgtgc 420
 ccacgcctgc tgagcacccc aagcccgatg cagccacccc cagacgaggc ccgcagggac 480
 atggccgggg acaccagtg gtccaggtgt ggcgggggtg aggggagggg ggtggggagc 540
 ggtggagatg gggccgtggg gagggagctg agatactgcc acgtgggacg atgctaggtg 600
 gggaggctg agctggggcg gctcctctgg ctgtggggcc cctgtgttc cttgtgggag 660
 gtggaaggaa gtgagtgtcc tgtccttct cctgtccatg agattccagg accggacctg 720
 gcaagtgtcc tatcccagcc agtgttctct gggctcttcc aggcagggt atgttccca 780
 ggccaggggc attgtcctgg acagtccagg ggcatacccc tcgccaggtg gaaccacct 840
 gtgtatgcat gaccctgaca agcaggcgcc aggacagtea ggaggccag 889

<210> SEQ ID NO 122
 <211> LENGTH: 863
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 122

gttgttgggt gtgaatggag aactgtgggc cctccccgac accttccagc gggacggcaa 60
 cgggggcccc gggggtgggc gccatcaacc ccgtcccacc gccaggacgg cgcgggggag 120
 ggccggcggg ggcggggcgt cctgtaaggc gcggccccc cccgcgggcg gggcggcatt 180
 cctgggaggg cggcgctctg acgtggaccc gggggccgcg ggcacggcgg gggggcggcg 240
 gtccgggggc ttettaaacc ccccgcccc gcccagcccc cacttcccga gcaccgctcc 300
 gacctgggag ggagagagag ccagagagcg gccgagcgcc taggaggccc gccgagcctc 360
 gccagcccc gccagcccc gcgcgagaga agttggagag gagagcagcg cagcgcagcg 420
 agtcccgtgg tcgcgcccc acagcggccc acagccccg atagccaaa cgcgggcct 480
 agccccggcc gcacccccag cccgcgccag catgatgaac aacagcggct actcagacgc 540
 cggcctcggc ctgggcgatg agacagacga gatgccgtcc acggagaagg acctggcgga 600
 ggacgcgccc tggaagaaga tccagcagaa cacattcacg cgctgggtgca atgagcacct 660
 caagtgcgtg ggcaagcggc tgaccgacct gcagcgcgac ctcagcagcg ggtccggct 720
 catcgcgctg ctcgaggtgc tcagccagaa gcgcatgtac cgcaagtcc atccgcgccc 780
 caacttccgc caaatgaagc tggagaacgt gtccgtggcc ctcgagttcc tcgagcgcga 840

-continued

gcacatcaag ctogtgccta tag 863

<210> SEQ ID NO 123
 <211> LENGTH: 2198
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 123

aagagaggca cactccctct accacaccga gggagggggc gttgagctga gaaaggttga 60
 gagaatgagg gaccaggtta ggtggacatc ggccaagaaa ggaaccacag cgggaggtaa 120
 gaccgagagt ccccagcttg aagcgtcacc actccgggat tcccagattc caacgcgagc 180
 ctgggaaag cccacagtgg agagagtccg gctggcaggg aatggccta ccccggggt 240
 gaaatctcgg agggctcgtc agccgagtcg cgcctctgcg ctgatgcgtg agagatgccg 300
 gacgtcgcgt ttgcctgtgc gacctcgcg gatgctgtgc agtcttggtc ccctctgcgt 360
 gtgtctaacg ccgaatgctg gtgtctcgag gtgtgagctt cggggccggg gtctttaaag 420
 aaccaaagat tcttaaggag tgatgatctg ggtagagcgg cccgacgtag ccgcgctccc 480
 aggtctcggg gcgagtcctg cggacagacc agaggagacc tgctggccag atgccccggg 540
 cccaaggcgg acgccagact gtctctgcgc cagccgggct ggccttcgga atggatcagg 600
 caccggggag gccggagtgg atctcagacc ctcaagccgg gaacaaacc gtcgatgcc 660
 gtgggcctgg agtccgcctc ctcttccc ccccaccct acccctgctt ccgaaaggct 720
 tcttcgctgg tcagtagctg cgtgcccgtc tgctgagggc tgggtcagaa ttggcgggct 780
 ggtaacgacc ccgtgcacaa gcggctccca gtctctccag aaagggccga tgactaaggg 840
 gtgggggtgg gggcgagggg ctggaagggt ttagggaaga acgtagcgg cctatcctgt 900
 cttcagcagc gccctctcat cttctagctc tgacccgag cagagcagtt ggagctcggg 960
 actgggaact gctggaattc ctatttagac ttctagacag tctagaaaca agaacttctc 1020
 tttccctggg cctcagtttc cttgtctgta aaatcaaaag gcgggctcta ggtgtaggcc 1080
 ttcttttcgc ttggtgatcc tggattcctt tccttgatc cgtggggagg ggttggcagc 1140
 aacagtccag ggcgttgccc gtctctgtcc tcaagtaegt agtccccgtg ccgcgccct 1200
 caacaccccc agcagccccc ccccctaagc ccgcagagca gggagctgag tgggaggggc 1260
 agaggggggg ccggttccca gtcctgctg gcggactaga gtggcgcggg ctgagcgtaa 1320
 aacctgggat agccactccc ccttttcctt atccccgccc cctgcccatt ggtcccggg 1380
 agaggttgac atcaaaagcc cggctctata taagccagat ccgcagggga gtccgcagaa 1440
 gggtaaaaca ggtctttggg ctcggcgac ctgcgccg cgagaaaccg gtaagaagac 1500
 agtgggctgc gcgtctcatt ttcagccttg ccggactct cccaaagccg gcgcccagta 1560
 gtggctccag agcccacagg tggccccgg cagtctctgg ggcgcattgga gcggcgttaa 1620
 tagggctggc ggcgcaggcc agtagccgct ccaacatgaa cctcgtgggc agctacgcac 1680
 accatcacca ccataccac ccgcaccctg cgcaccccat gctccacgaa cccttcctct 1740
 tcggtccggc ctgcgctgt catcaggaaa ggccctactt ccagagctgg ctgctgagcc 1800
 cggctgacgc tgccccggac ttccctgccc gcgggcccgc gcccgcgccc gctgcagccg 1860
 ccaccgcta tggctctgac gccaggcctg ggcagagccc cggggcgtg gaggcgcttg 1920
 gcggccgtct tggccggcgg aaaggctcag gaccaagaa ggagcggaga cgcactgaga 1980

-continued

gcattaacag cgcattcgcg gagttgcgcg agtgcacccc caacgtgccg gccgacacca	2040
agctctccaa gatcaagact ctgcgcctag ccaccagcta catcgcctac ctgatggacg	2100
tgctggccaa ggatgcacag tctggcgatc ccgagccctt caaggctgaa ctcaagaagg	2160
cggatggcgg ccgtgagagc aagcggaaaa gggagctg	2198

<210> SEQ ID NO 124

<211> LENGTH: 1945

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 124

ctggatgaca gagtgagact ccgtctcaaa aaaaaagctc catttgggag gccgaggagg	60
gtggattacc tgaggtcagg agtttgagac cagcctggcc cacataggga aaccccatct	120
ctactaaaaa tacaaaaatt agtcaggtgt ggtggctgac acctataatc ccagctactt	180
gggaagctga gccagggaga atcacttgaa ccggggaggt ggaggttgca gtgagctgag	240
atcatgccac tgcactccag cctggcgac agggtgagat tctgtctcaa acaacaaaat	300
ttaaaagctc cgaatcctcc aaaaatacca agattttcct gtcggtaact agagatgggt	360
actgatgatt atttttaata ggtgatttc aaagatgtga acgttatcca tggagattta	420
agtctccaaa aggaaaaaaa atgcatacct ttatactaaa acttcacac cagtcaaatt	480
tggatcatca ctaaattggc ttctacacct ctctcctaat ataaggtact tgtgtaagtt	540
tgcagttgtg agacacttat ttctcattt ttaatgtctt ctcagtaggg cactgatata	600
agtcactatt tgactgacca gaatggttg cactggtgat tggctcataa agtgcctcgc	660
attaggggg ctcaattatc aaaggtttaa atcctagccc aaaccattgc tgtgatgggg	720
gttaatcaat gaaccactca gcttcacttg caaaaagcggg atcacaatag ccgctttcgt	780
catgaccag cctaggtgag atttagtact taagtacact gccaggcaca caaggttaat	840
ttaacaattt aacacatttg ttctctatc catttctcca aaccttccaa ctaatcctaa	900
cgttcgttcg gccaaatggg ccaggaatc acttaacaa aaacaaaaaa caaaacaaac	960
aaaaaacac tccctggggc ttggggaagg aggcaccgcc gcccatgtcg cagtctgggg	1020
gtggctcagt cctcagcacc cagatctacg gccataatgc tcttcgagge caaggagccc	1080
ggatgcgggg cgttgccgaa ggcgtcttc tcaggctgag ggaaaggaga ggggtgggag	1140
cggggtgggg gcactcgcag ccagggaag gcggcgagtc gccgtcttcg agtcccacct	1200
gtccgaagcg ggtgagaaaa aggcaaaaca tggcaaagcc atgcacctcc cagggtgggc	1260
aactcacggc cggtgaaacg cggaccctta gcagtttcca gaccttggga accggaagcg	1320
gagctgaga gcgcgcccga gagggcgtga acgggaccgc tttcccgaa gtgcttgccg	1380
cctctgccc gcgagctgcc ccggggtctc tctggtttcc taatcagggc aacgccgagg	1440
gagagaacct ttaccttggc tgcactaagt tctcggtgcc actcctggc agggcgggac	1500
cttgtttagg cctgtgatc gcgcggttc tagtagcgca aggcgcagag tggaccttga	1560
cccgcctagg gcgggaagag tttggcccgc cgggtcccaa agggcagaat ggacgggctc	1620
ctaaatccca gggaatcctc taaattcatt gcagaaaaca gtcgggatgt gtttattgac	1680
agcggaggcg tacggagggt ggcagagctg ctgctggcca aggcggcggg gccagagctg	1740
cgctggagg ggtgaaagc cctctatgag ctgaacccca gggcggccga cgaggccgcg	1800

-continued

```

gtcaactggg tgttcgtgac agacacgctc aacttctcct tttggtcgga gcaggacgag 1860
cacaagtgtg tggtagagta cagagggaaa acatacagtg ggtactggtc cctgtgcgcc 1920
gccgtcaaca gagccctcga cgaag 1945

```

```

<210> SEQ ID NO 125
<211> LENGTH: 2379
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 125

```

```

aagcttggg tttacttggg cctctgcctc atctttcttc tttgctgctt cagcctgcgc 60
attcgttcc tccactagcg tctcatggtg cagaggttcc caagaagatg ggtgaaggc 120
cgagatcatt tggttatatt ataaaataga atgcaaatc acacaagttt ttgtttttta 180
tttatttatt tttttagaga tgaggtcttg ctatgttgtt tagtctggtc tcgaactcct 240
ggcctcgtga tccctcccacc ttgacctccc aaagtgctgg gattacaggc ctgaggcctg 300
agccactaca cccaactgaa ttcacatctt ttttttctt ttctgagacg gactctcact 360
ctgtcaccca gtatggagtg cagtggcgcg actgcccctc actgcaagct cegtctctcg 420
ggttcaagtg atttctatgc ctcagccccc caagtagctg gaattacagg ggtgcaactac 480
cacacctggc taatttttct gtttttagtag agatgggggtt tcaccatggt gcctgggtctc 540
aaactcctga cttaagtga tccacacacc tcagcctccc aaagtgctgg gattacaggt 600
gtgagcctcc acaccggcc gaattcacat gaattttaa gtgatgtctt caaagtgggt 660
tcaactgtgg gatgggcagc tttttgttat acatctagaa cgttctctt ctgtttctat 720
gaatactcgg ttggaagggt ctgaaaaacg gtcttaagag attatctgat tcgtttccca 780
gttttattac tcacatatca gctgtaattt gagcacgttt tctgattgag acaagactca 840
gatggtatta aacattacta caacacatcc gggcacggtg gctcacgctt gtaatcccag 900
cactttggga ggcggagggc ggcggatcac gaggtcagga gatcgagacc atcctggcta 960
acacggtgaa gccctgtctc tactaaaaat acaaaaaatt aggcgggcat ggtggcgggc 1020
gccctgtagc ccagctactc gggaggctga ggcaggagaa tggcgtgaac cgggagggcg 1080
gagcttgtag tgagcgcaga tcgcgccact gcactccagc ctgggcgaca gagcaagact 1140
ccatctcaa aaaaaaaaaa aaaaaaaaaa actacaacac tataaattca tatctattat 1200
aatagtactt tgtgcagggc cctaccctaa gtccttaacc gaaccggaa gcgagaagat 1260
gacttttgtt tgtttttaga gatgggcgcc tggctctgtc gccagcctgg agtgtggggg 1320
cgcgatctcg actcacagca gcctccacct cccgagttca ggcgatctt ctcctcagc 1380
ccctcgagga gctgggacca ccggcgcgct ccategcgcc cggetaggag ctgactttga 1440
atccgggctc tgcgcctggc cttctgcac tctataaggg aagacatctg tgacctcggg 1500
gcaaaggtea aattagatcc tgggtaggat cctgttcccg ctgcccctcg ggctggcact 1560
gccaggagta ctcagagctc aaagctggga tctgcagtcc cttaccact cagtgcacgc 1620
cgctaaggc tttgcgctc acctttactc acctcgaagc cctggacatc cgcactctgc 1680
ctaagacttc tcacctcagt agcagaagga agtcgctgca gctggccaca gectctctcc 1740
taggagaccg tccgggaaaa gcgagtcagg gtagaccctg agggccctca gctccggcta 1800
ttttcagatc tgtcgtctct tcacctcag cctttcaaac aggccactcc aaaaaaagc 1860

```

-continued

```

ccaatcacag ccttccttct tctcctggcc ttccggcact gtccaatcaa cgtacgccat 1920
ctatcgggta gtgggtgttc ggggccaccc ttcccgtgg tttccctcgt ggtgtgtaaa 1980
ggcagagagg aaaggcgagg ggtgttgacg ccaggaaggt tccatcttgg ttaagggcag 2040
gagtcctta cggacttgtc tgaggaaaga caggaaagcg ccagcatctc caccttcccc 2100
ggaagcctcc ctttgccagg cagaaagggg ttcccatggg gccgcccctg gcgcccgcgc 2160
cggcccacgt acccggggag gccggggccc ggaggacgag ggaaagcagg ccggggcgccg 2220
tgagcttcgc ggacgtggcc gtgtacttct ctcccagga gtgggaatgc ctgcccag 2280
cgcagagggc cctgtaccgg gacgtgatgc gggagacctt cggccacctg ggcgcgctgg 2340
gtgaggccgg gccctccggc cgggaccccc agtccgctg 2379

```

```

<210> SEQ ID NO 126
<211> LENGTH: 933
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 126

```

```

gagacgtact ctggctctgt cgcccaggct ggagcgcaat ggcgccatct cggcgcactg 60
caacctccac ctcccgggtt caagcgatc tactgctca gctcccag tagctgggac 120
tacaggcgcg cactaccaag cccggctaat ttcttttga tttttagtag agactgggtt 180
tcacgatgtt gcccgggctg gtctggaagt cttgacctca agcgtgcgcc ctctccgcca 240
ctgggtaagg cggggggcgg aatagggggc ttgcaatttc aactagagg cgggcgccgt 300
gggggaaaga agagtcaact ctcccacggt tcgtagagga aggcctgcct gagcctggag 360
cggggggcgg agagccacag tttggcatcc ccaggcatc cccagcccg cagactacca 420
ggcctccaga ggacaggacc ccacccccgg ccacaggccc tgccccagc actccccgca 480
ccccgctcc aagactctc cgcccactcc gcaccaact tataaaaacc gtcctcgggc 540
gcgcggggga gaagccgagc tgagcggatc ctcacacgac tgtgatccga ttctttccag 600
cggcttctgc aaccaagcgg gtcttaccoc cggctcctcc cgtctccagt cctcgcacct 660
ggaaccccaa cgtcccagag agtcccggaa tcccgcctcc caggctacct aagaggatga 720
gcggtgctcc gacggccggg gcagccctga tgetctgcgc cgccaccgcc gtgctactga 780
gcgctcaggg cggaccctgt cagtccaagt cgcgcgctt tgcgtcctgg gacgagatga 840
atgtcctggc gcacggactc ctgcccgtcg gccaggggct gcgcgaacac gcggagcgca 900
cccgcagcca gctgagcgcg ctggagcggc gcc 933

```

```

<210> SEQ ID NO 127
<211> LENGTH: 6096
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 127

```

```

atctgcacct cctcatatag ggttgatcca agtttcacag acatcactga gttcttagtg 60
gactcagcta ttggggctgt tctcacactt ttttttctt tgcaagaatc agcaatgggt 120
gcaagtggac ctgtgttaga cgtccagtga aacattgtgt tgggtaatca gctagaatcc 180
atccaagaac tcagccagcc tgggtgtggg tgagatctga tccttgaatg tcctcagtg 240
gcttttaggg ctggcagggt cagaagggcc ctctcatcac cccccaggg cctcattcct 300

```

-continued

tgtttaacac tttgctatca cagtottgaa tccttgtaat tgaacaatgg accccacatt	360
ttcactttgc actggtttct gattctgtaa ccgatcctgt cccctctct tgtctcattc	420
actctgggaa ttgtccccc attctgagac ctttcagcag tgcccacacg aggttctctgc	480
ccttatetga agctccacc tcacccccat ggcggaaccg caggcagccc tgettttgcg	540
tcccgcgtag gcaggctgtg caccggagtc acgacccct gattcagcct aggcagccac	600
agcttgactg ctcccgcgg acaagcccta ctgtgctatc tgccgctctt cccttctct	660
tcccaggggg tcgcgctcag gggaggcgca gctgtgtgca ttccgggagc ttcagacccc	720
cgtgtccagc agctccttcg tttcctgggt gctggggcgg ccttcccagc gaagagctca	780
actcagcggg acgtttggag gctctctgcc ccaaggcgtc ggggagtggt cggcgggaca	840
gtcgtgcttg cctttttcac tttcagagtg tccacgcccc acccgtttg tcaactgcagg	900
tcagtccagt ccagcccggc ccaccccacc ggtgcgtgtc tgtcgcacgt ggcagacgcc	960
atactctctg ttctgttta aagcccagga tctactgggc cctggaggca agaggtgaa	1020
gcagcggaa ccacgtgag ctgcccggga acggagcttc caaccccaga aggaggactc	1080
tgtgctccta caccttaacc ctttttagcc cgaacttct ccaacttctc tggccttgtt	1140
tagagctcga cagcgcgcc ccctggcgtc cgttgtgagg acagtagagg agagaggcaa	1200
gggtgtttt aaacagttt cctctacca ttatgggggc gacccgaggg ggagacccac	1260
tcttccgat tcccggtaag tgaaccaccg gaagaggtcg aaagtgcgg attcccatgt	1320
cctctccag ccccccccc accctgccc tccacaggac ggtggctctt cagtgcctt	1380
tgccgagcaa gtggcgttc tatgcacgtg ggtatcaatt cggactctgg acgaaatgga	1440
aacctcetta gccagccggc gtgggatcag ctgggacct gcgcgctccc ctggggggtt	1500
gccagccact ctgttgggt gcaagaagca ccatccttcg gaagctgggc cgaactggc	1560
caggctgact cgctcccacg cgcccgcctc taccggcgc cgcagcaatt cacctgccac	1620
cgctctgag ccgggtccgg acttcggcgc cctgacagtg tcccgcgac tccccacc	1680
gatgagatgg ggtctggcgt tggccagtgc gtgtccagg actcgcgggt ccctggccag	1740
ccatggggca gagggcgtg gtgttaggcc agtcttccc accctgccc gtcaccccag	1800
ccacaccac tgtctgtga ggccaagcgc gctccgctgg tttcctgagc caggcacctt	1860
ggccgcggac aggatccagc tgtctctcct tgcgacctg tcttcggga agtccacgtc	1920
ctaggcaggt cctcccaaag tgcccttggc gccgatcacc cctcccagcg tcttgacagt	1980
cctgtgcacc acctcccca ctcccattc aaagcctct tctctgaagt ctccggttcc	2040
cagagctctt gcaatccagg ctttcttgg aagtggctgt aacatgatg aaaagaaaga	2100
aaggaggacc aagagatgaa agagggctgc acgcgtgggg gcccgagtgg tggcgggga	2160
cagtcgtctt gttacagggg tgctggcctt ccctggcgc tgcccctgtc ggccccgcc	2220
gagaacctcc ctgcgcagc gcagggttta ctcatcccgg caggtgatc ccatgcgcga	2280
ggcgggcgc aaggcggcc agagaacca gcaatccag tatgcgcat cagcccttc	2340
caccaggcac ttcctctct tcccgaacg tccagggagg gagggcggg cacttataaa	2400
ctcagaccct ggccgatcc catgtcagag gctgcctcgc aggggctgcg cgcagcggca	2460
agaagtgtct gggctgggac ggacaggaga ggctgtcgc atcggcgtcc tgtgccctc	2520
tgtccggca cggcctgtc gcagtgcgc cgcttcccc ggccctgca cgcggcgcgc	2580

-continued

ctgggtaaca tgettggggt cctggtcctt ggcgcgctgg cctggcccg cctgggggttc	2640
cccgcacccg cagagccgca gccgggtggc agccagtgcg tcgagcacga ctgcttcgcg	2700
ctctaccggt gcccccgcac ctctctcaat gccagtcaga tctgcgacgg actgccccggc	2760
cacctaatga cagtgcgctc ctcgggtggct gccagatgca tttccttctc actgaacggc	2820
gacggcggcg ttggccgccc gcgcctctgg atcggcctgc agctgccacc cggctgcggc	2880
gaccccaagc gcctcggggc cctgcgcggc ttccagtggg ttacgggaga caacaacacc	2940
agctatagca ggtgggcacg gctcgacctc aatggggctc ccctctgcgg cccgttctgc	3000
gtcgtgtctc ccgctgctga ggccactgtg cccagcgcgc cgatctggga ggagcagcag	3060
tgcaagtga aggccgatgg ctctctctgc gagttccact tcccagccac ctgcaggcca	3120
ctggctgtgg agccccggcg cgcggctgcc gccgtctcga tcacctacgg cccccgttc	3180
gcggccccgc gagcggactt ccaggcctgc ccggtgggca gctccgccgc ggtggctccc	3240
ctcggcttac agctaattgtg caccgcgccg cccggagcgg tccaggggca ctgggcccagg	3300
gaggcgcggc gcgcttgga ctgcagcgtg gagaacggcg gctgcgagca cgcgtgcaat	3360
gcgatccctg gggctccccg ctgccagtgc ccagccggcg ccgcctgca ggagcaggg	3420
cgtcctgca ccgcatccgc gacgcagtcc tgcaacgacc tctgcgagca cttctgcgtt	3480
ccccaccccg accagccggg ctctactctg tgcatgtgcg agaccggcta ccggtggcg	3540
gccgaccaac accggtgcga ggacgtggat gactgcatac tggagcccag tccgtgtccg	3600
cagcgtgtg tcaaacacaca ggggtggcttc gactgcccact gctaccctaa ctacgacctg	3660
gtggacggcg agtgtgtgga gcccggtggc ccgtgcttca gagccaactg cgagtaccag	3720
tgccagcccc tgaacaaaac tagctacctc tcgctctgcg ccgagggctt cgcgccatt	3780
ccccacgagc cgcacagggt ccagatgttt tgcaaccaga ctgcctgtcc agccgactgc	3840
gaccccaaca cccaggttag ctgtgagtgc cctgaaggct acatcctgga cgacggtttc	3900
atctgcacgg acatcgacga gtgcgaaaa gccggcttct gctccggggt gtgccacaac	3960
ctccccgta ccttcgagtg catctgcggg cccgactcgg cccttgcccg ccacattggc	4020
accgactgtg actccggcaa ggtggacggg ggcgacagcg gctctggcga gcccccgcc	4080
agccccagc ccggtccac cttgactcct ccggccgtgg ggtcgtgca ttggggcttg	4140
ctcataggca tctccatcgc gagcctgtgc ctggtgggtg cgtttttggc gctcctctgc	4200
cacctgcgca agaagcaggg gcgccccagg gccaaagtgg agtacaagtg cgcggcccct	4260
tccaaggagg tagtctgca gcacgtgcgg accgagcggg cgcgcagag actctgagcg	4320
gcctccgtcc aggagcctgt ctccgtccag gacccctgtc ctctcacc ccagctttgc	4380
taccaaaagca ccttagctgg cattacagct ggagaagacc ctccccgac cccccaaagct	4440
gttttcttct attccatggc taactggcga gggggtgatt agaggaggga gaatgagcct	4500
cggcctcttc cgtgacgtca ctggaccact gggcaatgat ggcaattttg taacgaagac	4560
acagactgcg atttgtccca ggtcctcact accgggcgca ggagggtgag cgttattggt	4620
cggcagcctt ctgggcagac cttgacctgc tgggctaggg atgactaaaa tatttatatt	4680
ttttaagtat ttaggttttt tttgttttcc tttgttctta cctgtatgct tccagtatcc	4740
actttgcaca gctctccggt ctctctctct ctacaaactc ccacttgtca tgtgacaggt	4800
aaactatctt ggtgaatttt ttttctctag ccctctcaca tttatgaagc aagccccact	4860

-continued

tattccccat tcttcctagt tttctcctcc caggaactgg gccaaactcac ctgagtcacc	4920
ctacctgtgc ctgacctac ttcttttgct cttagctgto tgctcagaca gaaccacctac	4980
atgaaacaga aacaaaaaca ctaaaaaataa aaatggccat ttgctttttc accagatttg	5040
ctaatttata ctgaaatttc agattcccag agcaaaaaa ttttaaaaa aggttgagat	5100
gtaaaaggta ttaaattgat gttgctggac tgtcatagaa attacacca aagaggatt	5160
tatctttact tttaaacagt gagcctgaat tttgttgctg ttttgatttg tactgaaaa	5220
tggaattgt tgtaaatctt cttatgcaat ttcctttttt gttattatta cttatttttg	5280
acagtgttga aaatgttcag aaggttgctc tagattgaga gaagagaca acacctcca	5340
ggagacagtt caagaaagt tcaaaactgca tgattcatgc caattagcaa ttgactgtca	5400
ctgttccttg tcaactgtag accaaaaataa aaccagctct actggtcttg tggaaattggg	5460
agcttgggaa tggatcctgg aggatgccca attagggcct agccttaac aggtcctcag	5520
agaatttcta ccatttcaga gaggcctttt ggaatgtggc ccctgaaca gaattggaag	5580
ctgccctgcc catgggagct ggttagaaat gcagaatcct aggctccacc ccatccagtt	5640
catgagaatc tatatttaac aagatctgca gggggtgtgt ctgctcagta atttgaggac	5700
aaccattoca gactgettcc aattttctgg aatacatgaa atatagatca gttataagta	5760
gcaggccaag tcagccctt attttcaaga aactgaggaa ttttctttgt gtagctttgc	5820
tctttgtag aaaaggctag gtacacagct ctagacactg ccacacaggg tctgcaaggt	5880
ctttggttca gctaagctag gaatgaaatc ctgcttcagt gtatggaaat aaatgtatca	5940
tagaaatgta acttttgtaa gacaaagggt ttcctcttct attttgtaaa ctcaaaatat	6000
ttgtacatag ttatttattt attggagata atctagaaca caggcaaaat ccttgcttat	6060
gacatcactt gtacaaaata aacaaataac aatgtg	6096

<210> SEQ ID NO 128

<211> LENGTH: 2500

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 128

accacttct gtgtgtggat agtatectgc aggagagatg ttgtctgcag tgtgagctgg	60
gccaccgga gtgtgtgaat aggatcctgc aggagaaatg gaatccggag tgtgagctgc	120
atccgctgta gagggtggat aaaatcctgc aggaaagatg gcactcggaa tgtcagcggg	180
agccaccgac ctctgaggat gcaccccgca ggtgtgatgc ggggccagtt ccaaggctgg	240
gtagggttt accctggctt ctgtgttgta ctctcattct ctctctttt cttctaatac	300
ctgctctggg aggcacagc ccatgtccag tgtgcaggcc atggagacc acacggcaag	360
gaactggaac cccctgccag cagcctcggg ggtccagtcc ttagatggtg cctgtggtc	420
agcaatgcac ctgtgacctc cgggctatgt ctctgtgtag ttgcttttgt gttttaacat	480
agcaacagga aactagccta ttaccacca atcccattcc aggetgcttt caaacgcagc	540
tcaggctaga acaccagcag ggggacacag ctgagacttg gggtttgcga cgggaacacg	600
cccattctgt gcctctgaat ctggcaccgt caccctgtgg cctgggttca gcaacttggc	660
ctcaccctcc ttgtctgtga aattcagact gggctcttgt gagatgattg gagagaatgt	720
atgaactatg tgagaacgcc acctttgtgc gtatctcagc cagtgtcttc cctccttcc	780

-continued

```

aaagtcttct gctgtctcta gacacacccg acgtgggggg ggggggttcc ctgggtctcc 840
tcctaggtct gtcccaggag ggcacgcact gaaggccgag agaatcccgg gggctgcatt 900
gcgccgcgcc aaggactcca cacaggacct ttcattttcc caactgtgct gagccaggcg 960
gccggcagag agcagggtgg tgacaggccc cggggagccg gaccgcctgg gtetaatctt 1020
cccgcagact cccttctgtt gcgctttggg gcttgggcct cagtttcttc aaaaggaatg 1080
aggggctttt ttggaacgtt aaataatttc ctacgtggtt ggggtaggg agaaggagaa 1140
agagaggagc ggcctgcgc gcctggaatc gtgcccggat cagagcaagc gctctaaaag 1200
tgttacaaac attaaaggcc caactaaaaa acccgtagtg agcgcaggca gaaaccacgg 1260
gtaagagaag tggagaagct tcgctgtagc ccagggtcc cgagcccga gtctcgagcg 1320
cagaatcagg ggtgccaatg ctctctcccg cgcgccggag cgctcgctt ggccatgccc 1380
gccgccccac cgggatgagc gcgctcagc cggacgctgg ggcgccgggt tctcgccccg 1440
ccccgcctc ggggattcag aggggcccgg aggagcctcg cgcagtgtca cagctggcgc 1500
ccccgcctc cgcgcacag ctgggacgtg ggccgcggcc gggcgggccc agtcgggagc 1560
cggccgtggt ggctcctgtc gtccgagcgt ccgctcgcgc cgctcgccat ggccaagcgc 1620
tccaggggcc ccggggcccg ctgctgttg gcgctcgtgc tgtttctgcg ctgggggacg 1680
ctggccgtgg tggcccagaa gccggggcca ggggttccga gccctgctt gtgcttccgc 1740
accacctgc gctgcatgca tctgtctgtg gaggcctgc ccgccgtggc gccgcagacc 1800
tccatcctgt gactgcccgc ggggaccccg ggggcccggg gtcccgggct tctgggagat 1860
ccgggagcgc aggggtgatc ggaggtgggg ggcgcggagg gtggaggggg catcgggccc 1920
gcggggggcc tggggacttg ggacgcagaa gggaaacctc gaaggggggac gtggggggac 1980
ctgggcccgg ggaccctgtt ggcctttggt cgcctcgcgg gagacgccga ggggcccgaac 2040
agagcgtgt gcgcccggcc ttcgtagccc cctttgttcg gaactcggaa tccccgagg 2100
actgggaagt tgttgagacc tccggggctc cccccctcgc cctcccgcgg cccctctca 2160
tgctccgccc gctcccctt tccccctggt tcgcccgcct tctcctcctc accttcccc 2220
cgctcaggac cctcggctc ccctccgctc ccgagcgcg gcgcagcccc ctccgtctc 2280
ccagccccct ccgcccgtt cctcgtcctg ttegtcccc tctcctcctc ctctctctc 2340
tccccctct cctcctctc ccctctctc tctcctctc ctctcctc ctctctctt 2400
cccctctct tccccctt ccttctctc ccccagctc cgcctctct cctcccccg 2460
ccccttgag cgcagtcccc accccatccc cccgcgccg 2500

```

<210> SEQ ID NO 129

<211> LENGTH: 2200

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 129

```

cctcgcctcc tccagccggc cccccgggccc cctcctctcg gcgcccggac cttggccctc 60
cctctctctt ccaacttctc tctttgccct aacttcgccc ccataccccg ctcaattctc 120
ctgcaccccg ggctcgccaa tccctcttcc caagtcctc ttccagcccg gcttctctc 180
cgggttcgccc ccccttctcc ccaatctccg tctcttctcc tcccttcgccc ctccccctc 240
tcttctctct tccccctacc caacctggt tccccctggt cctcagtcct gatctctcc 300

```

-continued

```

ttactctgtc ccgcccact ctgcccggc ctctcagtcc gggttgagcc ccacgtgtgg 360
acggccggcg ccccaactgac agcccggccc cgccggcccc ccccggcccc cgccgggcct 420
ctaaaacccc cgccggcgcc cctcccacgc cgcactcttct ccagcgccca gcctcccgcc 480
ctctctcttg ctggccgcac gcccggcccc cgccgacctc cgccgggttc cgcagccgct 540
acccggcctt cgttgccctg tgggactccg agcggagccc gagggaaacc tcctcttctt 600
ctggggggcga cttttgtttg cttgctctgt tctttctggt gacttttgca gctttccaat 660
atccgtcttc ggagcgcacg ggaatccgcc gagctctgcy tgcaggccct tttttctttt 720
gaggttcaca tttttgaaa ttttacgcca gggcttttgt aatttcctcc cccgcccgct 780
gacggctctg gagtcgctcg gggctttagg ccggttatgc aacgtgtacc gctcggggct 840
gccggctgca cctcccggc gcctccggcc tcaactgctg agaccggcg ccccgctct 900
cgcttcggcg gcagtcaggg gggccggcct ctgtcagagt ctccagctag agcaggggagc 960
ccgagcccga gggagtcccc ggagccgacg aagggttat tagaccctga ctctttctg 1020
aggcggcgag atttgtctt tgatcactcc ctctccggcg gtctacggcc ggcgctttc 1080
ggcggcgggc atggggagaa gacggaggct gtgtctccag ctctacttcc tgtggctggg 1140
ctgtgtggtg ctctggggc agggcacggc cggccagcct cagcctctc cgcccaagcc 1200
gccccggccc cagccggccc cgcaacaggt tcggtccgct acagcaggct ctgaaggcgg 1260
gtttctagcg cccagtatc gcgaggaggg tgccgcagtg gccagccggc tccgcccggc 1320
aggacagcag gacgtgctcc gagggtaagt gggcaagcgg ctccgcacct agggctccgg 1380
cttgggggag gggggaatcc tcagtttggc ggctttctgg cccactccgt cccagaccct 1440
ttagctggag cctagagctg cagccccctt tgccagaata tccaaagacc cccaggagcg 1500
cgtccccctt ttccttcca accccgcagc tcagcggggc gaaagccctc tctccggggg 1560
ttggggggcg ggtggttagg ggggtccagg gtgccgatcg cagagcgtgt gcagagctcg 1620
cgctcgggga acaggttctg aatgtccggc ggcagcggcg cctgggtccg cctgctgcag 1680
gggcccagaga agcctgcttg ctccccacgt cggggccgcc gctcgtgagc cttttgtttg 1740
aggacgtgtg cagggttcac agctcacctt ctcatcgtca acccgagcgc tccaccttgc 1800
gacgcgcttt ccttgacacg tcggggccaa agtaacagtt gaccaaggag gaatggattt 1860
gggaaggagg gcaaggattc tttggaacgg aatggtccct ttgttctctg catctggaag 1920
ctagaatagt agcaaattat atgtttccat gcctcttttc gccctttaa aaggcaggca 1980
agggacgaca gatgaaaggc agtgtttaga cttttctgac cctcctgcat tccagcatct 2040
agctcttttg ctccaacgtc tgctcccga tctccaataa tttgaagtgt aattttgatt 2100
tgtttgttgt cctgaaatct actcgtcgg ggcattgctt acgaagaccg tttatatgtt 2160
gctgcatccc tctacctatc tgttacgtga ccgcttctgt 2200

```

<210> SEQ ID NO 130

<211> LENGTH: 2000

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 130

```

ttggaagaaa aggatctccg aggaaggggc tgagagaagg gcagggtgaa ctggactaaa 60
ggccagagta ggaaggagaa gagggggcaa aaaagaaggg gatgaaatta agcacagaag 120

```

-continued

```

atgggtaaag aaaaaagtat cagggaaag gcaaaataag agaaagcctt gaggataaga 180
gggtagaagg ctaaagaaca aggggaccac tgggtcgggg aagcgctgcc tgaacggcgg 240
gacagtgaca aagaaggggc gctggcgata ttcgcaccaa ggggtgcgaaa cgcaatcggg 300
aggtgagaaa tggaaagaag gcgaatgccc ggctacaagt agcctgggac tgaaggggga 360
cctgggggag gggctgggccc cagggcagaa aagtccaggt tcccatgcgg cctgggccc 420
cgtggagcgg gcgctgaatc accgttcage cccccccctc cctcctccc cgaccgggtc 480
ccgcagtccc cgectcctcg gccgccgct ccacggggcg gggccctggc cgggaccag 540
cgccgcggct ataaatgggc tgcggcgagg ccggcagaac gctgtgacag ccacacgccc 600
caaggcctcc aagatgagct acacgttgga ctcgctgggc aaccgctccg cctaccggcg 660
ggtaaccgag acccgctcga gcttcagccg cgtcagcggc tcccctcca gtggttccg 720
ctcgcagtcg tggctcccg gctcgcacc caccgtgtcc tctcctata agcgcagcat 780
gctcgcctcg cgctcgttt acagctcggc catgctcagc tccgccgaga gcagcctga 840
cttcagccag tctcgtccc tgctcaacgg cggctccgga cccggcgcg actacaagct 900
gtcccgtccc aacgagaagg agcagctgca ggggtgaac gaccgcttg cgggtacat 960
agagaagggt cactacctgg agcagcagaa taaggagatt gaggcggaga tccaggcgt 1020
gcggcagaag caggcctcgc acgcccagct gggcgacgcg tacgaccagg agatccgca 1080
gctgcgcgcc accctggaga tgggtgaacca cgagaaggct caggtgcagc tggactcga 1140
ccacctggag gaagacatcc accggctcaa ggagcgttt gaggaggagg cgcggttgcg 1200
cgacgacact gaggcgcca tccgcgcgct gcgcaaagac atcgaggagg cgtcgtggt 1260
caaggtggag ctggacaaga aggtgcagtc gctgcaggat gaggtggcct tctgcggag 1320
caaccacgag gaggaggtgg ccgaccttct ggcccagatc caggcatcgc acatcacggt 1380
ggagcgcaaa gactacctga agacagacat ctcgacggcg ctgaaggaaa tccgctcca 1440
gctcgaagc cactcagacc agaatatgca ccaggccgaa gagtgggtca aatgccgcta 1500
cgccaagctc accgagggcg ccgagcagaa caaggaggcc atccgctccg ccaaggaaga 1560
gatcgcgag taccggcgcc agctgcagtc caagagcatc gagctagagt cggtgcgcg 1620
caccaaggag tccctggagc ggcagctcag cgacatcgag gagcgccaca accacacct 1680
cagcagctac caggtaggaa ccgcggtgc gcggccagcc tgcgccagcg ccagcgcgc 1740
gcgccccga caettgggct cgtgccagc gcctctctcc gccgcgctcc ctggtggcg 1800
ctcgtagag cagcgcgccc gcagacctag ggtatttgcg gatcagcgtc ctgcacctc 1860
tcctcctcca cactcgcgcc ccaccacct gcccagctg ctaagggtct tgacctttt 1920
cagaaacgtg catcttttcc agttctaatt ttgcaagctt gcacgtttaa agcaggagg 1980
atgaattcgg tagtggataa 2000

```

<210> SEQ ID NO 131

<211> LENGTH: 2300

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 131

```

tcagattgtc attgggaggg tgaataaatg aatgcttga ttatgagagt ttggggcag 60
aatatgccca cagactctta tctgaagcca tcagatttag tggtgcgaa cccaccgaag 120

```

-continued

tcagggattt acatttttta cagcaacgag agaaaacttc ccttttctc tgcagaagt	180
aggactggat ctcaaaaata gaaatgtgtc ctctaaatg tgtgccatc cccgtggtg	240
acaaaacacg gatttcccaa gatagctgcc acacacttgg tttctaactc ctgtattgct	300
tccccgccag aatgtogaag tccttccga atatgccag tcatacttc tgaactttg	360
agcaaacacc gtccggcttc ttgtgcttc ctcaaagacc ccaggcaccg gcagggagga	420
cacaggcccg ggcagagcgc ccttgcgog gggttctctg ccaactccgc ccagcctgcg	480
gcgcaaacgc tcttctcagc cgcagtccca cccgctgctg gcaatctgaa tgaggagccg	540
cgctattttt acctccccg ctgcaatcct ttatatttac atgcaggaag caaatatata	600
aggattaag aaggagatgc gtggccttag ttatccaga gcaggaagag gttggaatag	660
gagaggtat gtgaagtctg ggggtggtga aaaggcaggt ggacttcggc tggttgttt	720
ctccgatca tcctgtctc tggcctggaa acccccgtac tctctttctt ctggcttacc	780
cgtgactgcc ggtccccct ccacgcccc catcttttga ggtaccacc gtcacctccg	840
atgctgcttg ggtctctgca tcaactctgct gctttacccc cttccccgcc cccaacaaa	900
gcctgcgcag tgcgttccgg gccaggcaac agcagcagca cagcatccag caacagcatc	960
agcaccgaa gccccgctcg ggcgctctc cggggggcgg ggcgcacgc cgtcccgcc	1020
gtccccgcgc cgtctctcc cgcgcctccc cgcgcctctc gctccccgc gccgctcag	1080
catcctcagg cccggcgca gccccgcag tcgctgaagc ggccgcgcc gccggggag	1140
ggagtagccg ctggggagcg tccaagtgg cggagcggcg aggaacctg gactcctctg	1200
cgctccgcc cgggagtgcc tgcgaggcta ggcgagcccg gaaagggggc gccgcccagc	1260
cccagcccc gcgccccgtg ccccgagccc ggagccccct gcccgccgcg gcacctgcg	1320
cgcgagccg cgtgaccgg ctccgcccc ggcgccccg cagctagccc ggcgctctcg	1380
ccggccacac ggagcggcgc ccgggagcta tgagccatga agccgccccg cagcagctcg	1440
cggcagccgc cctggcggg ctgcagcctt gccgcgctt cctgcggccc ccaacgcgcc	1500
cccccggtt cggtgctgc cagcgcctcc gccgcacgc cgcctgccc cctgcttctc	1560
gtccttctc tctgctctc cctgcggcc tctccggc cccgctctg ggggctgct	1620
gcgcccagcg gtgggtatgg ccccgctccc tttgcttgg ctttccccg gggcctgca	1680
gaggaaagcg aaggcgccgc gggctcgtgt gctccgggt tgtccccgc tcggccttc	1740
cttccctccc tgcctgtctt tccaccttc tcttccca accccattc atcccagttc	1800
acttttgaa gtccatttct gttgcattcg cgaatacccc attccaattc ttgttggttc	1860
cactgggagg tgtttagtgg atcctgggtc cctcagcgat ctctgtgcaa cttgcccagg	1920
ggcaaccagt ggtgggaaa tacagcgagg gagcaagttg ctacttgcgt ggtggaacct	1980
taatgtgaat gcggggagga tgtagtgata atagtggtaa tgggctgttt cctcaaatt	2040
cgtatccggc gcattcagtg cggttggaat taagtgggg gaggcacct tcggggacca	2100
aagaattaag gtgctgaaga catactctat gcacacctt tggttctgat ttctcaaagt	2160
gcttgctatt ataataaata attaatataa taccatcttc tataattga tgattggaag	2220
tactgaaag cagaaagctg gctttgtcag gaaaaataaa agaaattggg aagctgccag	2280
catctgtacc cctacatggc	2300

-continued

<211> LENGTH: 3000

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 132

```

tactgccgac tttaggtctc tctggatctc aggccccctt ctctaagatg catcctagag    60
gaccaaaaat acactttatt tgggcttcgc ctgcttttgt ggaagggtag tttactagag    120
gatataatct cgtgttttaa tttgctctct ctctaaagg aaatgtggag aaaaaaaaaa    180
agcagaaatt gaaataaacc aatatttagt ttatttcatt cgattcttag gggaaactgg    240
gaggagccta agatgatatt cccttcctag agaaagaatc caaagtccag gaaatagcg    300
acaggggagt tcaagactgc ccctgctagt ccttccttgg ctactctccg ctgcatcgc    360
aggatagctc tcattagcag gagaatcggg caagtgtgtg gataagtaga gagtgtgttg    420
aacaacttgt aacgttttat gaaatacgc tttgtcatgt tcctaaaag gctttgcgga    480
agccgtttgt ctttactaat caagtcttta cttacacaaa agtagaagta gaagtagttt    540
tagaaaacat actaacaatc ttctatcccc ttgaagacca gagtagcaga aaacaggtga    600
tttgatttat aaaattgcac tcaacttttc ctcttctcag atttcacatt acattagccc    660
atltgtgtta cgtgtgataa aaaatggaac aggcgcctcc actgcattgt tctcctttaa    720
aaatagatca cttacacctt aactttgttt tccttaaatt cgattcttaa caggagagct    780
ttctattatt tcagatggag tgaggttgca cgactgggat ggaagaaagg aatcccttaa    840
atltggggga atttctgttc tctgttccaa gaccatttta cttgggggtg ggggggtggc    900
gcggcggtca gggcagtgga acgcagtcgc ggctgcgcca tccctgcact tccaggcgcg    960
cgggagggac cggcggggac gcgagctgcg gactctggcg aactcggggg aggcagacag    1020
ggggagggcg acaccagcc ggcagggcgc tcagcctccc cgcagccggc gggcctttct    1080
cctgacagct ccagaaaagg cagaccctt cccagccag ccaggtaagg taaagactgc    1140
tgttgagctt gctgttactg agggcgcaca gaccctgggg agaccgaagc ttgccactgc    1200
gggattctgt ggggtaacct gggctctacg aagtctcctg aaagagggga gaagggtttg    1260
cattttctct atggaggatt cttctctctc tagcatttct tttgatgtat tcaactggta    1320
gaagtgagat ttaaacaggt agcagagagc gctcacgtgg aggaggtttg gggcgcgcg    1380
gcccacccc caccctctc cgggaccgcg cctatttcta aagttacacg tcgacgaact    1440
aacctatgct ttaaatctc ctttcagcc ccgtgagtc gggcgacat tggccctgtg    1500
ggtggtctgg aacggtcccc tctccggaa aaaccagaga acggttggga gagctgaaac    1560
gagcgtccgc gacgaggtcc gtgcagaacc gggcttcagg accgctgagc tccgtagggc    1620
gtccttgggg gacgccaggt gcgcgctcc tctgcccctg ttgagatgga caacgcctcg    1680
ttctcggagc cctggcccgc caacgcatcg ggcccggacc cggcgtgag ctgctccaac    1740
gcgtcagctc tggcgcgct gccggcgcc ctggcggtgg ctgtaccagt tgtctacgcg    1800
gtgatctgcg ccgtgggtct ggcgggcaac tccgcctgct tgtaactgtt gctgcgggcg    1860
ccccgcatga agaccgtcac caacctgttc atcctcaacc tggccatcgc cgacgagctc    1920
ttcacgctgg tgctgcccac caacatcgcc gacttctctg tggcgagtg gccctcggg    1980
gagctcatgt gcaagctcat cgtggctatc gaccagtaca acacctctc cagcctctac    2040
ttcctcaccg tcatgagcgc cgaccgctac ctggtggtgt tggccactgc ggagtcgccc    2100

```

-continued

```

cgggtggccg gccgcaccta cagcgcgcg cgcgcggtga gctggccgt gtgggggatc 2160
gtcacactcg tcgtgtgcc cttegcagtc ttgcgccggc tagacgacga gcagggccgg 2220
cgccagtgcg tgctagtctt tccgcagccc gaggccttct ggtggcgcgc gagccgcctc 2280
tacacgctcg tgctgggett egccatcccc gtgtccacca tctgtgtcct ctataccacc 2340
ctgtgtgcc ggctgcatgc catgcggctg gacagccacg ccaaggccct ggagcgcgcc 2400
aagaagcggg tgaccttctt ggtggtggca atcctggcgg tgtgctcct ctgctggacg 2460
ccctaccacc tgagcacctg ggtggcgctc accaccgacc tcccgcagac gccgctggtc 2520
atcgctatct cctacttcat caccagcctg agctacgcca acagctgctt caacccttc 2580
ctctacgctt tcttgagcgc cagcttccgc aggaacctcc gccagctgat aacttgccgc 2640
gcggcagcct gactccccca gcgtccggct ccgcaactgc ccgccactcc tggccagcga 2700
gggaggagcc ggcgccagag tgcgggacca gacagccgcg ctaggcctcc tggggaacc 2760
gactcgcgcc ccatacccga cctagcagat cggaaagcgt gcgactgtgc ccgcaggtg 2820
accttgccaa gccctccagg tgatgcggcg ccatgccggg tgaggagaac tgaggctgag 2880
atgccacac tgagggtctc ctaaagccga ggtggaggaa gaggagggtg gaggaggagg 2940
gcggtattgc tgggaaccgc cccctccctg cctgctccc tgctgcccc cccgagcct 3000

```

<210> SEQ ID NO 133

<211> LENGTH: 3000

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 133

```

gaatacatta aagtggggc aacccttgag ccagacttc tgccatgtga agacccttg 60
aaaatcctga caaacacagg tactgcgtaa gtggtcagct aattaaagag gggaggtgga 120
gctgtccttt gtgtatccaa taagtaccca ttatctcatt tgagcatgaa aagaggccac 180
tgttattact ttaagaagg aaagtaagca ggatagctca tatttttaga accattcctc 240
accaaattga ataattccgg tgaaaagtgg gagtggaggaa gaaagaaaa aaaaacttct 300
aatcataatg tttgggaata agaaaaggag aagaaactca cgtcaaagcc gactttctcc 360
tgcagctgta aaataaactc ttaagacctc tctgctgaa actctggaga ggaaaactgg 420
agtggcgggt gggctttgcc tgcagctcaa ctctccctcg cggcggggc gcggctgggt 480
tcagcacctc gaaagcgc cctcgcggcg ccccgggatt acgcatgctc cttggggccc 540
gccgccttgg ccgtgcaagt gccaccgtaa ctggtgagag ccgctggcaa cccaccgga 600
gttgacaacc gcggagagac gcagacacc actgacctcc aggaagctga gcgtggtgga 660
tggaaactca cgatctctt ctctccaagg acggaacct catccaagca gtcccagagg 720
aaacggataa aggtatttga aagggagcga gcggcccaa atgcacaat tgagcggctg 780
ggggagtat gcgccagtgc cccagtgacc gcgggacacg gagaggggaa gtctgcgttg 840
tacataagga cctagggact ccgagcttgg cctgagaacc cttggacgcc gagtgcttgc 900
cttacgggct gcaactccta actctgctcc aaagcagccg ctgagctcaa ctctgcgctc 960
cagggcgctc gctgcgcgcc aggacgcgct tagtaccag ttctgggct ctctcttcag 1020
tagctgcttt gaaagctccc acgcacgtcc cgcaggctag cctggcaaca aaactggggt 1080
aaaccgtggt atcttaggtc ttgtccccc gaacatgacc tagaggtacc tgcgcatgca 1140

```

-continued

gatggccgat gcagccacga tagccaccat gaataaggca gcaggcgggg acaagctage	1200
agaactcttc agtctggtcc cggaccttct ggaggcggcc aacacgagtg gtaacgcgtc	1260
gctgcagctt ccggacttgt ggtgggagct ggggctggag ttgccggacg gcgcgccgcc	1320
aggacatccc ccgggcagcg gcggggcaga gagcgcggac acagaggccc gggtgccgat	1380
tctcatcagc gtggtgtact ggggtgtgtg cgcctggggg ttggcgggca acctgctggt	1440
tctctacctg atgaagagca tgcagggtg gcgcaagtcc tctatcaacc tcttcgtcac	1500
caacctggcg ctgacggact ttcagtttgt gtcaccctg cccttctggg cggtgagaaa	1560
cgctcttgac ttaaaatggc ccttcggcaa ggccatgtgt aagatcgtgt ccatggtgac	1620
gtccatgaac atgtacgcca gcgtgttctt cctcactgcc atgagtgtga cgcgctacca	1680
ttcgggtggc tcggtcttga agagccaccg gacccgagga cacggccggg gcgactgctg	1740
cggccggagc ctgggggaca gctgctgctt ctcggccaag gcgctgtgtg tgtggatctg	1800
ggctttggcc gcgctggcct cgtgcccag tgccatttcc tccaccacgg tcaagtgat	1860
gggcgaggag ctgtgectgt tgcttttccc ggacaagttg ctgggcccgc acaggcagtt	1920
ctggctgggc ctctaccact cgcagaaggt gctgctgggc ttctgtctgc cgtgggcat	1980
cattatcttg tgtaactgc tgctggtgcg ctctatcgcc gaccgccgcg cggcggggac	2040
caaaggaggg gccgcggtag ccggaggacg cccgaccgga gccagcgcgc ggagactgtc	2100
gaaggtcacc aaatcagtga ccatcgttgt cctgtccttc ttctgtgtt ggctgcccac	2160
ccaggcgcct accacctgga gcacacctat caagttcaac gcggtgcctc tcagccagga	2220
gtatttctct tgccaggat acgcgttccc tgtgagcgtg tgcctagcgc actccaacag	2280
ctgcctcaac ccgctcctc actgcctcgt gcgcgcgag ttccgcaagg cgtcaagag	2340
cctgctgtgg cgcctcctc ctctctcgt caccagcatg cgcctctca ccgccaactac	2400
caagccggag cacgaggatc aggggctgca ggccccggcg ccgccccacg cggcccgga	2460
gccggacctg ctctactacc cacctggcgt cgtggtctac agcggggggc gctacgacct	2520
gctgcccagc agctctgct actgacgcag gcctcaggcc cagggcgcgc cgtcggggca	2580
aggtggcctt ccccgggcgg taaagaggtg aaaggatgaa ggagggtgg ggggggccc	2640
atttaagaag taggtgggag gaggatgggc agagcatgga ggaggagcct gtggataggc	2700
cgaggacctt ctctggagag gagatgctc gaaatcaggt ggagagagga aattggcaaa	2760
gggatagaga cgagccccac gggccagaca gccaacctcc gctccgcacc ccacagcctc	2820
tccttactct tcccacgctg agtagtgtgg gggcggccag aagcgaagac aagcagcaaa	2880
aatgtagaga aattggcagc gggagcgggg cttagccaaa tgatgcacag acaattgtgc	2940
ccgtttatc cagcgacttc tgcggagagg gcagccgtcg gcacaaaac tcctttgct	3000

<210> SEQ ID NO 134

<211> LENGTH: 2200

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 134

gtccccgat tcctcacc atcatataac gtgtgtatatt attatgttc cegtttctc	60
tgtctccgcc agcagaatgt aaactccatg aggtcaggaa tctccgagtt atgttgccc	120
agtgtaatcc aagagcccgg aacagtgcct ggcacacagc gggcatatgg aagaacaaat	180

-continued

gtgtgaaggt gtgaatgaat gaataattga aagaataaat agtagttctc agcctcacag	240
aacacgggtc acaacctcaa atgacctgct accctgcccc taaataacag agatgcagga	300
gtaagtgtctg ggctgtgacc tgtcaacatg ctaagccgct caaacaaaac tgccccaacag	360
cccgtgggcc gcctatttgc agcaactgggc cctgagccgc acattcccat ttcggtgata	420
aagaaactga ccagatagtt taagtggcct gctgcggaag acagagctgg tctgcaccg	480
gtcgtgctt cccagctct tttttggcct cttttctgac ggcagcaga cccagttct	540
ggagagtctg tcactgcctc cccgtggtgg gagatcagag gctggtgtc cttgggagcg	600
gcgagcggtg ctgcgcgag gatagaaagg gactgcgcgc ccgagtcccc cagatccctg	660
ggaaccgcg ccacctccc gccctgccc atccccggcc gcgctgtcag tctccattag	720
cgctaacagg ctccagacgg agcgggcccg gcgctgggtt aatgcaatcg gcgcttacc	780
tggggcgcag gctacattac cagcccggcc cccgccaggc acggccagaa ccagtcagcc	840
cgccctctgc cggccgcccc gcgcctccag ctcttccccg gccccgcccg aacgccacac	900
ggcggagccc agccccagcc gcgcctctag agcctgccc aaaggccgccc gtcgggggccc	960
ggcagggcgc aaggcaccag ggatccccct gcgcgcggac acgtgagtgc gcctgagcg	1020
cgggacaggg ctaggctctc ctgggagggc cgggcccaga cgcgccagca gagggctagc	1080
gagttttag tgcagtgcag ttaagtgtcc gagaaggctc ctgtggctgt tgaagtgtcg	1140
cggacctgag ctggggaggg ggtcggcacg ctgccctcag cctcggtag tccaatcca	1200
gccatttggg gcagccgaga gtgggtgaac gaggaaaagt gctgcagggc cttcagccc	1260
ccccagaggg ctgtcagaag tctccaactc ttgagttccg gcgtgcccc acctctgttt	1320
ccaaattttt ccagcggagc cgcgctcttt tctgggaacc ctgcgtccgc tcagcgcgcg	1380
ctcatcccag tgtctaaggc gctcccgggt ggtcttggga gttgcaagta gggaggaacg	1440
gccgggtaac cacctctttt ccctttatcc aagcagagcc tcggcgtgcc cccagaccg	1500
gtaaagtcc tctcgcagc cgcacccatg cttctggcgc ggatgaacc gcaggtgag	1560
cccgagaaca acggggcggc cacgggtcca gagcagcccc ttcgggcgcg caaaactgcg	1620
gagctgctgg tggtaagga gcgcaacggc gtccagtgcc tgcggcgcgc ccgagcggc	1680
gacgcgcagc cccgggagac ctggggcaag aagatcgact tctgctgtc cgtagtcggc	1740
ttcgcagtgg acctggccaa cgtgtggcgc tccccctacc tctgctacaa gaacggcgcg	1800
ggtgagcgtg gggtcgggct gggaatttga atctgggagg tccactgtct gcagcgggtg	1860
ctgggacagg agctggaata cacacggaag ggaggcagag agacaggggc aaatctgggg	1920
cgcagaaaga actggacagc gctaacggga aaaaaaaaaag attggagtcc tctggaaggt	1980
cattttccca ggtcttttgc agagtacctc gagctcattc cagcggaggt gtcaggattg	2040
ggcaccctgg aagcaaaaca gcagaagagt gaaatcgagt catgacctc aagtcatggt	2100
aggggtatgg atggaaagga cagaatctgg ggtgccaggt tgggtggggg agcctgacct	2160
ttgatggtc tgcgggaagg gaggtggaga ttccaagagc	2200

1. A method of quantifying or detecting methylated DNA in a target DNA region possessed by genomic DNA contained in a biological specimen, comprising:

First step of separating double-stranded DNA derived from genomic DNA comprising the target DNA region contained in the biological specimen into single-stranded DNA;

Second step of mixing the single-stranded DNA, a methylated DNA antibody, and a specific oligonucleotide comprising a nucleotide sequence of a part of a complementary sequence to any of the following nucleotide sequences and not inhibiting binding between the methylated target DNA region in the single-stranded DNA and the methylated DNA antibody, to form a complex of the single-stranded DNA, the methylated DNA antibody, and the specific oligonucleotide; and

Third step of detecting or quantifying the methylated DNA in the target DNA region contained in the biological specimen by conducting detection or quantification depending on an identification function that is possessed by the methylated DNA antibody contained in the complex and available for detection:

- (1) the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (2) the nucleotide sequence of SEQ ID NO:2 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (3) the nucleotide sequence of SEQ ID NO:3 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (4) the nucleotide sequence of SEQ ID NO:4 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (5) the nucleotide sequence of SEQ ID NO:5 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (6) the nucleotide sequence of SEQ ID NO:6 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (7) the nucleotide sequence of SEQ ID NO:7 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (8) the nucleotide sequence of SEQ ID NO:8 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (9) the nucleotide sequence of SEQ ID NO:9 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (10) the nucleotide sequence of SEQ ID NO:10 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (11) the nucleotide sequence of SEQ ID NO:11 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (12) the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having 80% or more sequence identity to the sequence,
- (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:1 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(11) the complementary sequence to the nucleotide sequence of SEQ ID NO:2 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(15) the complementary sequence to the nucleotide sequence of SEQ ID NO:3 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(16) the complementary sequence to the nucleotide sequence of SEQ ID NO:4 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(17) the complementary sequence to the nucleotide sequence of SEQ ID NO:5 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(18) the complementary sequence to the nucleotide sequence of SEQ ID NO:6 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(19) the complementary sequence to the nucleotide sequence of SEQ ID NO:7 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(20) the complementary sequence to the nucleotide sequence of SEQ ID NO:8 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(21) the complementary sequence to the nucleotide sequence of SEQ ID NO:9 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(22) the complementary sequence to the nucleotide sequence of SEQ ID NO:10 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence,

(23) the complementary sequence to the nucleotide sequence of SEQ ID NO:11 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence, and

(24) the complementary sequence to the nucleotide sequence of SEQ ID NO:12 or a nucleotide sequence having 80% or more sequence identity to the complementary sequence.

2. The method according to claim 1, wherein the specific oligonucleotide comprises any of the following nucleotide sequences:

- (1) the nucleotide sequence of SEQ ID NO:13,
- (2) the nucleotide sequence of SEQ ID NO:14,
- (3) the nucleotide sequence of SEQ ID NO:15,
- (4) the nucleotide sequence of SEQ ID NO:16,
- (5) the nucleotide sequence of SEQ ID NO:17,
- (6) the nucleotide sequence of SEQ ID NO:18,
- (7) the nucleotide sequence of SEQ ID NO:19,
- (8) the nucleotide sequence of SEQ ID NO:20,
- (9) the nucleotide sequence of SEQ ID NO:21,
- (10) the nucleotide sequence of SEQ ID NO:22,
- (11) the nucleotide sequence of SEQ ID NO:23
- (12) the nucleotide sequence of SEQ ID NO:24,
- (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:13,
- (14) the complementary sequence to the nucleotide sequence of SEQ ID NO:14,

- (15) the complementary sequence to the nucleotide sequence of SEQ ID NO:15,
- (16) the complementary sequence to the nucleotide sequence of SEQ ID NO:16,
- (17) the complementary sequence to the nucleotide sequence of SEQ ID NO:17,
- (18) the complementary sequence to the nucleotide sequence of SEQ ID NO:18,
- (19) the complementary sequence to the nucleotide sequence of SEQ ID NO:19,
- (20) the complementary sequence to the nucleotide sequence of SEQ ID NO:20,
- (21) the complementary sequence to the nucleotide sequence of SEQ ID NO:21,
- (22) the complementary sequence to the nucleotide sequence of SEQ ID NO:22,
- (23) the complementary sequence to the nucleotide sequence of SEQ ID NO:23, and
- (24) the complementary sequence to the nucleotide sequence of SEQ ID NO:24.
3. The method according to claim 1, wherein a counter oligonucleotide is added in forming the complex in the Second step.
4. The method according to claim 1, wherein formation of the complex in the Second step is conducted in a reaction system containing a divalent cation.
5. The method according to claim 1, wherein the methylated DNA antibody in the complex formed in the Second step has been made to bind to a support before the Third step.
6. The method according to claim 1, further comprising, after the First step and before the Third step, the step of digesting unmethylated single-stranded DNA with a methylation sensitive restriction enzyme capable of digesting single-stranded DNA.
7. The method according to claim 1, further comprising, after the First step and before the Third step, the step of digesting unmethylated single-stranded DNA with a methylation-sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide comprising a recognition sequence for the methylation sensitive restriction enzyme as a part thereof.
8. The method according to claim 6, wherein the methylation sensitive restriction enzyme capable of digesting single-stranded DNA is HhaI.
9. The method according to claim 1, wherein the methylated DNA antibody is a methylcytosine antibody.
10. The method according to claim 1, wherein the biological specimen is mammalian blood, serum, plasma, bodily fluid, cell lysate or tissue lysate.
11. The method according to claim 1, wherein the DNA sample derived from genomic DNA contained in the biological specimen is digested in advance with a restriction enzyme recognition cleaving site for which is not present in the target DNA region of the genomic DNA.
12. The method according to claim 1, wherein the DNA sample derived from genomic DNA contained in the biological specimen has been digested with a methylation sensitive restriction enzyme.
13. The method according to claim 1, wherein the DNA sample derived from genomic DNA contained in the biological specimen has been digested with a methylation sensitive restriction enzyme in a reaction system containing a specific masking oligonucleotide.
14. The method according to claim 7, wherein the methylation sensitive restriction enzyme is HpaII or HhaI.
15. The method according to claim 1, wherein the DNA sample derived from genomic DNA contained in the biological specimen is a DNA sample purified in advance.
16. The method according to claim 1, wherein the target DNA region possessed by genomic DNA comprises a recognition cleaving site for the methylation sensitive restriction enzyme.
17. DNA comprising any of the following nucleotide sequences:
- (1) the nucleotide sequence of SEQ ID NO:13,
 - (2) the nucleotide sequence of SEQ ID NO:14,
 - (3) the nucleotide sequence of SEQ ID NO:15,
 - (4) the nucleotide sequence of SEQ ID NO:16,
 - (5) the nucleotide sequence of SEQ ID NO:17,
 - (6) the nucleotide sequence of SEQ ID NO:18,
 - (7) the nucleotide sequence of SEQ ID NO:19,
 - (8) the nucleotide sequence of SEQ ID NO:20,
 - (9) the nucleotide sequence of SEQ ID NO:21,
 - (10) the nucleotide sequence of SEQ ID NO:22,
 - (11) the nucleotide sequence of SEQ ID NO:23
 - (12) the nucleotide sequence of SEQ ID NO:24,
 - (13) the complementary sequence to the nucleotide sequence of SEQ ID NO:13,
 - (14) the complementary sequence to the nucleotide sequence of SEQ ID NO:14,
 - (15) the complementary sequence to the nucleotide sequence of SEQ ID NO:15,
 - (16) the complementary sequence to the nucleotide sequence of SEQ ID NO:16,
 - (17) the complementary sequence to the nucleotide sequence of SEQ ID NO:17,
 - (18) the complementary sequence to the nucleotide sequence of SEQ ID NO:18,
 - (19) the complementary sequence to the nucleotide sequence of SEQ ID NO:19,
 - (20) the complementary sequence to the nucleotide sequence of SEQ ID NO:20,
 - (21) the complementary sequence to the nucleotide sequence of SEQ ID NO:21,
 - (22) the complementary sequence to the nucleotide sequence of SEQ ID NO:22,
 - (23) the complementary sequence to the nucleotide sequence of SEQ ID NO:23, and
 - (24) the complementary sequence to the nucleotide sequence of SEQ ID NO:24.

* * * * *

专利名称(译)	测量DNA甲基化的方法		
公开(公告)号	US20110039273A1	公开(公告)日	2011-02-17
申请号	US12/936296	申请日	2009-04-06
[标]申请(专利权)人(译)	住友化学有限公司		
申请(专利权)人(译)	住友化学公司		
当前申请(专利权)人(译)	住友化学公司		
[标]发明人	TOMIGAHARA YOSHITAKA SATOH HIDEO TARUI HIROKAZU		
发明人	TOMIGAHARA, YOSHITAKA SATOH, HIDEO TARUI, HIROKAZU		
IPC分类号	C12Q1/68 C07H21/04 G01N33/543 G01N33/53		
CPC分类号	C12Q1/6804 C12Q1/6827 C12Q1/6834 C12Q2600/154 Y10T436/143333 G01N33/5308 C12Q2537/164 C12Q2521/331 C12Q2563/131		
优先权	2008098006 2008-04-04 JP		
外部链接	Espacenet USPTO		

摘要(译)

本发明涉及测量生物样本中包含的基因组DNA中的目标DNA区域中甲基化DNA含量的方法，等等。

Fig. 1

